var title_f26_12_26816="External otitis (including swimmer's ear)";
var content_f26_12_26816=[" <h1 id=\"patTopicTitle\">",
"  Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/12/26816/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26816/contributors\" id=\"au4245\">",
"       Laura A Goguen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/12/26816/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26816/contributors\" id=\"se6695\">",
"       Daniel G Deschler, MD, FACS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/12/26816/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26816/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?26/12/26816?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     External otitis is a condition that occurs when the ear canal becomes irritated. The ear canal is the part of the ear that leads from the outer ear to the ear drum (",
"     <a class=\"graphic graphic_figure graphicRef55121 \" href=\"UTD.htm?29/61/30677\">",
"      figure 1",
"     </a>",
"     ). External otitis can develop as a result of an infection, allergy, or skin problem. \"Swimmer's ear\" is the name for external otitis that occurs in a person who swims frequently.",
"    </p>",
"    <p>",
"     External otitis is different from otitis media (middle ear infections). When a person says that they have an ear infection, they usually mean that they have otitis media. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"      \"Patient information: Ear infections (otitis media) in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     This article will discuss external otitis that is caused by an infection, as well as ways to prevent future episodes of external otitis. More detailed information is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link\">",
"      \"External otitis: Pathogenesis, clinical features, and diagnosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      EXTERNAL OTITIS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Several factors can increase your risk of developing external otitis.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cleaning the ear canal removes ear wax. Ear wax serves to protect the ears from water, bacteria, and injury. Excessive cleaning or scratching can injure the skin, potentially leading to infection.",
"      </li>",
"      <li>",
"       Swimming on a regular basis removes some of the ear wax, allowing water to soften the skin. Bacteria, which normally live in the ear canal, can then enter the skin more easily.",
"      </li>",
"      <li>",
"       Wearing devices that block the ear canals, such as hearing aids, headphones, or ear plugs, can increase the risk of external otitis (if worn frequently) by injuring the skin.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      EXTERNAL OTITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptoms of external otitis include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pain in the outer ear, especially when the ear is pulled or moved",
"      </li>",
"      <li>",
"       Itchiness of the ear",
"      </li>",
"      <li>",
"       Fluid or pus leaking from the ear",
"      </li>",
"      <li>",
"       Difficulty hearing clearly",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      EXTERNAL OTITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If you think that you or your child could have external otitis, you should see a healthcare provider. Your provider will examine the outside and inside of your ear to confirm the diagnosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      EXTERNAL OTITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of external otitis aims to reduce pain and eliminate the infection. Most people with external otitis can be treated at home. If your infection is severe or your eardrum is ruptured, you will be referred to an ear-nose-and throat specialist (an otolaryngologist) for an examination and treatment.",
"    </p>",
"    <p>",
"     In some cases, your healthcare provider will flush out your ear with water and hydrogen peroxide before you begin treatment; this speeds healing by removing dead skin cells and excess ear wax.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Ear drops",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ear drops are usually prescribed to reduce pain and swelling caused by external otitis. It is important to apply the ear drops correctly so that they reach the ear canal:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Lie on your side or tilt your head towards the opposite shoulder.",
"      </li>",
"      <li>",
"       Fill the ear canal with drops.",
"      </li>",
"      <li>",
"       Lie on your side for 20 minutes or place a cotton ball in the ear canal for 20 minutes.",
"      </li>",
"      <li>",
"       Finish the entire course of treatment, even if you begin to feel better within a few days.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You should begin to feel better within 36 to 48 hours of starting treatment. If your pain worsens or does not improve within this time period, call your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Pain medication",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have bothersome ear pain, you can take a non-prescription pain medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Avoid getting ears wet",
"     </span>",
"     &nbsp;&mdash;&nbsp;During treatment, you should avoid getting the inside of your ears wet. While showering, you can place a cotton ball coated with petroleum jelly in the ear. However, you should not swim for 7 to 10 days after starting treatment. Avoid wearing hearing aids and in-ear headphones until pain improves.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      EXTERNAL OTITIS PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     The old saying, \"Don't put anything smaller than your elbow in your ear\" to clean the ear is true. The ear is self-cleaning; fingers, towels, cotton-tipped applicators, and other devices should not be used to clean the inside of the ears.",
"    </p>",
"    <p>",
"     If you feel that you need to clean excessive wax from your ears, talk to your healthcare provider first.",
"     <span class=\"nowrap\">",
"      S/he",
"     </span>",
"     may want to examine your ears to see if the ear wax is excessive. It is normal to have some ear wax (also called cerumen). If you have an excessive amount of ear wax, talk to your healthcare provider about safe ways to clean your ears. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12823?source=see_link\">",
"      \"Cerumen\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you swim frequently, experts recommend the following tips to reduce the chance of developing external otitis.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Shake your ears dry after swimming",
"      </li>",
"      <li>",
"       Blow dry your ears on a low setting, holding the dryer 12 inches away.",
"      </li>",
"      <li>",
"       Use ear drops after swimming to prevent ear infections; these are available at most pharmacies without a prescription.",
"      </li>",
"      <li>",
"       Consider wearing ear plugs made for swimming.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413328689\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18221028\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/2/15394?source=see_link\">",
"      Patient information: Outer ear infection (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/26/33186?source=see_link\">",
"      Patient information: Age-related hearing loss (presbycusis) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/46/32482?source=see_link\">",
"      Patient information: Ear wax impaction (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/57/10130?source=see_link\">",
"      Patient information: Removing objects stuck in the ear (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18221054\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12823?source=see_link\">",
"      Cerumen",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20216?source=see_link\">",
"      Malignant (necrotizing) external otitis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000622.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000622.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/healthyswimming/swimmers_ear.htm\">",
"      www.cdc.gov/healthyswimming/swimmers_ear.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       KidsHealth",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/kid/ill_injure/aches/swimmers_ear.html\">",
"      file://kidshealth.org/kid/ill_injure/aches/swimmers_ear.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?26/12/26816/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?26/12/26816?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26816/abstract/1\">",
"      Rosenfeld RM, Brown L, Cannon CR, et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg 2006; 134:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26816/abstract/2\">",
"      Rosenfeld RM, Singer M, Wasserman JM, Stinnett SS. Systematic review of topical antimicrobial therapy for acute otitis externa. Otolaryngol Head Neck Surg 2006; 134:S24.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f26_12_26816=[""].join("\n");
var outline_f26_12_26816=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           EXTERNAL OTITIS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           EXTERNAL OTITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           EXTERNAL OTITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           EXTERNAL OTITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           EXTERNAL OTITIS PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/61/30677\" title=\"figure 1\">",
"           Normal ear anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f26_12_26817="CPAM prenatal ultrasound_width x height";
var content_f26_12_26817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After measuring the longest dimension of the lesion (L), the probe is turned 90 degrees and the \"width\" (W) and \"height\" (H) of the lesion are measured. The L x W x H x 0.52 = volume of CPAM. The CPAM volume ratio (CVR) is then calculated by dividing the CPAM volume by the head circumference.",
"    <div class=\"footnotes\">",
"     *CPAM was previously known as congenital cystic adenomatoid malformation (CCAM)",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney Stephenson, MD and Andrew P Schuller, RDMS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26817=[""].join("\n");
var outline_f26_12_26817=null;
var title_f26_12_26818="Condyloma lata syphilis";
var content_f26_12_26818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Condyloma lata in the perineal region of a woman with secondary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous organisms are generally present in these lesions, which makes them highly infectious.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26818=[""].join("\n");
var outline_f26_12_26818=null;
var title_f26_12_26819="Perioral dermatitis papules";
var content_f26_12_26819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Perioral dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small erythematous papules are present around the mouth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26819=[""].join("\n");
var outline_f26_12_26819=null;
var title_f26_12_26820="Blood donation and transfusion";
var content_f26_12_26820=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Blood donation and transfusion (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/12/26820/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26820/contributors\" id=\"au498\">",
"       Steven Kleinman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/12/26820/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26820/contributors\" id=\"se5869\">",
"       Arthur J Silvergleid, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/12/26820/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26820/contributors\" id=\"de8736\">",
"       Jennifer S Tirnauer, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?26/12/26820?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Blood is essential for transporting oxygen, nutrients, and other substances to tissues throughout the body. Donated blood can be lifesaving for individuals who have lost blood because of accidents or surgery, as well as for people who have become severely anemic or have dangerously low platelet counts because of certain medical conditions",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     treatments. Screening measures help to maximize safety of blood donation for the donor and the recipient.",
"    </p>",
"    <p>",
"     For people who are considering donating blood, a local blood bank can describe the criteria for being a blood donor. The websites at the end of this topic also include information about eligibility criteria (see",
"     <a class=\"local\" href=\"#H23\">",
"      'Where to get more information'",
"     </a>",
"     below). People who have a pre-existing medical condition may wish to consult their own healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SCREENING MEASURES TO PROTECT THE DONOR",
"     </span>",
"    </p>",
"    <p>",
"     Several screening measures are used to ensure that blood donation is safe for the donor and is unlikely to have any negative health effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Medical history interview",
"     </span>",
"     &nbsp;&mdash;&nbsp;All blood donors are asked questions about their medical history to help determine whether they can safely donate blood without experiencing any negative health effects [",
"     <a class=\"abstract\" href=\"UTD.htm?26/12/26820/abstract/1\">",
"      1",
"     </a>",
"     ]. During the donation, one unit of blood (approximately 500 mL, or 17 fluid ounces) is removed.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Heart and lung disease &mdash; Potential donors are asked if they have ever had heart, lung, or blood diseases. In general, people with heart disease, heart valve conditions, irregular heartbeat, disease of the blood vessels in the brain, heart failure, and certain lung conditions are not allowed to donate blood unless this has been cleared with their healthcare provider.",
"      </li>",
"      <li>",
"       Other medical conditions &mdash; Potential donors are asked if they feel healthy and well on the day of donation.",
"      </li>",
"      <li>",
"       Seizures &mdash; People with a history of seizures can donate blood, provided they have had no seizures within a certain period of time (usually one to six months).",
"      </li>",
"      <li>",
"       Recent surgery &mdash; People who have undergone recent surgery are permitted to donate blood when healing is complete and they have resumed full activity. However, if a transfusion was given at the time of surgery, donation is not allowed for one year.",
"      </li>",
"      <li>",
"       Pregnancy &mdash; Women who are pregnant are not permitted to donate blood during pregnancy and for six weeks after the pregnancy ends.",
"      </li>",
"      <li>",
"       Age requirement &mdash; The minimum age for blood donation is 16 or 17 years, depending upon the state. When allowed, 16-year-olds must bring a signed permission form from a parent. In most cases, there is no upper age limit for donation, although approval from the donor's physician is required in some cases.",
"      </li>",
"      <li>",
"       Weight requirement &mdash; Individuals weighing less than 50 kg (110 pounds) are not permitted to donate blood. The less a donor weighs, the greater the likelihood of having a reaction, such as dizziness and fainting following donation. Although reactions to blood donation are rare, individuals weighing between 50 and 54 kg (110 and 119 pounds) are most likely to experience reactions. Most blood centers perform an additional evaluation of donors aged 16 to 18 who are just over the weight limit, which takes into account the donor&rsquo;s estimated blood volume, calculated from the donor&rsquo;s height and weight.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Medical evaluation",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to a medical history, donors undergo a brief physical examination before donation to check for any obvious signs of illness or conditions that would disqualify them from blood donation.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Vital signs &mdash; The pulse, blood pressure, and temperature of a donor are checked before donation. Individuals with a fever, high blood pressure, very high or very low heart rate (with the exception of highly conditioned athletes and those on beta blocker medication), or an irregular heart beat are temporarily not permitted to donate blood.",
"      </li>",
"      <li>",
"       Blood test &mdash; A small blood sample is taken from a fingerstick and tested to check for the number of red cells or the amount of hemoglobin in the blood. This is done to ensure that the donor is not anemic or likely to become anemic or iron deficient after they donate. Individuals with hemoglobin levels that are too low are temporarily not permitted to donate blood. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"        \"Patient information: Anemia caused by low iron (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Time interval until next donation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Donors are eligible to donate no sooner than 56 days after their previous donation. However, this minimum interval can vary, depending upon how rapidly the person's body is able to replenish their red blood cells. Some donors, especially women who have heavy menstrual periods, will not be able to donate every 56 days because their iron stores are not sufficient to replenish the lost red blood cells.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      APHERESIS DONATION",
"     </span>",
"    </p>",
"    <p>",
"     A technology called apheresis has made it possible to collect specific components of blood during the donation procedure. Apheresis is used to selectively collect red blood cells, platelets (blood components that play an important role in clotting), plasma, and granulocytes (a type of infection-fighting white blood cell).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Red blood cells &mdash; Donors can give red blood cells by apheresis once every 16 weeks. This is less frequent than whole blood donation because a greater amount of red blood cells are collected during the apheresis procedure.",
"      </li>",
"      <li>",
"       Platelets &mdash; Donors can give platelets up to 24 times per year. Approximately 1 percent of people have a mild reaction to one of the substances (citrate) that is mixed with the blood during platelet donation; the reaction can include feelings of numbness and tingling, muscle cramping, and nausea. The reaction can be treated or prevented by taking a calcium supplement before or during the donation.",
"      </li>",
"      <li>",
"       Granulocytes &mdash; Donors of granulocytes may be given granulocyte colony-stimulating factor (G-CSF)",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       a glucocorticoid medication called dexamethasone on the day before donation to increase the number of granulocytes in their blood. Glucocorticoids are usually not given to individuals who have diabetes, gastrointestinal ulcers, or glaucoma. The side effects of G-CSF and dexamethasone may include headache, joint pain, fatigue, insomnia, allergic reactions, and fever.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      SCREENING MEASURES TO PROTECT THE RECIPIENT",
"     </span>",
"    </p>",
"    <p>",
"     Screening of blood donors helps to ensure that the donated blood is safe for transfusion into a recipient. A variety of different measures are used for this screening.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Elimination of payment for donation &mdash; Since the late 1970s, volunteer donors have been the source of all whole blood and blood components in the United States. Donors are sometimes paid for donating plasma that is used to manufacture other blood products. However, to protect the recipient, these products undergo additional treatment to kill any infectious agents that might be in the product.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Screening for infections",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Human immunodeficiency virus (HIV)",
"     </span>",
"     &nbsp;&mdash;&nbsp;The human immunodeficiency virus (HIV) is the virus that causes AIDS. A variety of measures are used to screen donors for potential or actual HIV infection, including questioning the donor about any signs or symptoms of HIV and behaviors that increase the risk of HIV.",
"    </p>",
"    <p>",
"     People who want to be tested for HIV or other sexually transmitted infections should NOT donate blood for this purpose. Even though donated blood is tested for HIV, the tests are not perfect; a person who might have been exposed to HIV could transmit the virus to a recipient if they donate blood. Free and anonymous HIV testing is available elsewhere (see",
"     <a class=\"external\" href=\"file://www.hivtest.org/\">",
"      www.hivtest.org",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Hepatitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hepatitis is an infection that causes inflammation of the liver. Blood donors are routinely screened to determine whether they have or have been exposed to hepatitis.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People who have had viral hepatitis (A, B, or C) or hepatitis of unknown origin after their 11th birthday are permanently disqualified from donating blood.",
"      </li>",
"      <li>",
"       People who have ever had a positive test for hepatitis B surface antigen (a marker for hepatitis B) are permanently disqualified from donating blood.",
"      </li>",
"      <li>",
"       People who have had sexual contact or have lived in the same dwelling (eg, house, dormitory) with someone who has hepatitis (A, B, or symptomatic hepatitis C) are disqualified for 12 months after their last exposure to that person, depending upon the particulars of the exposure.",
"      </li>",
"      <li>",
"       People who have received a blood transfusion are not permitted to donate blood for 12 months after the date of transfusion.",
"      </li>",
"      <li>",
"       In some states, people who have received a tattoo or a body piercing are not permitted to donate blood for 12 months. In other states, where these industries are carefully regulated by state law to ensure that the procedures are sterile, earlier donation may be permitted without the need for any waiting period.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Parasitic diseases",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood donors are routinely asked questions about possible exposure to several parasitic diseases that can be transmitted by blood transfusion.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Malaria &mdash; Transfusion-transmitted malaria is common in some parts of the world but is extremely rare in the United States. Donors who have had malaria are not permitted to donate for three years after they become free of symptoms. Travelers to regions where malaria occurs are not permitted to donate blood for one year after they leave the area, provided they have not had symptoms of malaria. Immigrants from or residents of countries where malaria is common are not permitted to donate for three years after their departure from that country. (Residency is usually defined as living in the country for at least five years.)",
"      </li>",
"      <li>",
"       Chagas disease and babesiosis &mdash; Transmission of Chagas disease (American trypanosomiasis) by transfusion is rare in the United States. Blood donors are asked if they have ever had Chagas disease, and most donated blood is tested for Chagas disease.",
"       <br/>",
"       <br/>",
"       Transmission of babesiosis (a malaria-like illness spread by ticks) by transfusion is uncommon. Blood donors are asked if they have ever had this disease.",
"      </li>",
"      <li>",
"       Creutzfeldt-Jakob disease (CJD) and variant CJD &mdash; Creutzfeldt-Jakob disease (CJD) is a rare but fatal neurologic disease. Variant Creutzfeldt-Jakob disease (vCJD) is a somewhat similar disease that first appeared in the United Kingdom (UK) in 1996. Affected individuals may have no symptoms of CJD or vCJD for many years.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     To date, there have been no reported cases of transfusion-related transmission of CJD and only four reports of probable transmission of vCJD in the UK. Despite this extremely small (vCJD) risk, donors who meet one or more of the following criteria are not allowed to donate:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Have spent &ge;3 cumulative months in the UK from 1980 to 1996,",
"       <strong>",
"        or",
"       </strong>",
"      </li>",
"      <li>",
"       Have spent &ge;5 cumulative years in Europe from 1980 to present,",
"       <strong>",
"        or",
"       </strong>",
"      </li>",
"      <li>",
"       As current or former US military personnel, civilian military employees and their dependents, have lived for &ge;6 months at US military bases in Northern Europe from 1980 to 1990 or elsewhere in Europe from 1980 to 1996,",
"       <strong>",
"        or",
"       </strong>",
"      </li>",
"      <li>",
"       Received a blood transfusion in the UK or France between 1980 to present,",
"       <strong>",
"        or",
"       </strong>",
"      </li>",
"      <li>",
"       Injected bovine (from cows) insulin from the UK or other countries with a history of mad cow disease (bovine spongiform encephalopathy)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Bacterial infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bacteria can get into donated blood if a donor has a bacterial infection, if bacteria on the skin gets into the blood from the needle stick, or if there is a skin infection near the location where the blood is drawn. To reduce the likelihood of bacterial contamination of blood, the skin around the site is carefully examined and cleaned before the needle is inserted.",
"    </p>",
"    <p>",
"     Donors who have a fever, who do not feel well, or who are taking oral antibiotics (except for acne) are not permitted to donate blood. These restrictions also apply to individuals who are banking blood for their own use (see",
"     <a class=\"local\" href=\"#H21\">",
"      'Autologous blood donation'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Other medical conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;In order to protect the recipient against non-infectious complications, the donor is evaluated for certain medical conditions before blood donation.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cancer &mdash; There have been no reported cases of the transmission of cancer by blood transfusion. However, because such transmission is theoretically possible, donors are screened for a history of cancer.",
"       <br/>",
"       <br/>",
"       Donors who have had cancer of a solid organ or tissue (such as the lung, liver, breast) are permitted to donate if they have been symptom-free and cancer-free for a defined period of time, usually two to five years.",
"       <br/>",
"       <br/>",
"       Donors who have had blood cancers (such as leukemia or lymphoma) are permanently disqualified from donating.",
"       <br/>",
"       <br/>",
"       Donors who have had a superficial cancer that has been completely removed by surgery (such as basal cell cancer of the skin or early cervical cancer) can donate blood without any waiting period.",
"      </li>",
"      <li>",
"       Hemochromatosis &mdash; Individuals with hereditary hemochromatosis (a condition in which frequent removal of blood is the standard treatment) can donate their blood for transfusion if they meet other criteria for being a donor and if the blood bank has met certain regulations from the Food and Drug Administration (FDA). There is no risk of transmitting this condition to the recipient. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=see_link\">",
"        \"Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Recent vaccinations",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are strict standards for when you can donate blood after you have received a vaccination. When you go to donate blood, you will be asked if you have had any recent vaccinations. If you have, you might have to postpone your blood donation.",
"    </p>",
"    <p>",
"     For some live or attenuated (weakened) viral or bacterial vaccines (measles, mumps, oral polio, oral typhoid, yellow fever), you have to wait at least two weeks before donating your blood. For rubella or varicella zoster vaccines, you have to wait four weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most medications taken by donors do not pose a risk to recipients. However, five drugs are known to cause birth defects and are considered during donor screening:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Etretinate (Tegison&reg;), used for severe psoriasis",
"      </li>",
"      <li>",
"       Acitretin (Soriatane&reg;), also used for severe psoriasis",
"      </li>",
"      <li>",
"       Isotretinoin (Amnesteem, Sotret, Claravis, formerly known as Accutane&reg;), used for severe acne",
"      </li>",
"      <li>",
"       Finasteride (Propecia&reg;, Proscar&reg;), used for benign prostatic hypertrophy and hair loss",
"      </li>",
"      <li>",
"       Dutasteride (Avodart&reg;, Jalyn&reg;), usually given for prostatic enlargement",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Donors who have taken isotretinoin and finasteride are asked to wait one month after the last dose before donating blood; donors who have taken dutasteride are asked to wait six months; and donors who have taken acitretin are asked to wait three years. Individuals who have taken etretinate are permanently disqualified from donating blood.",
"    </p>",
"    <p>",
"     People who took aspirin or aspirin-containing medications within the previous 48 hours are allowed to donate whole blood but are not allowed to donate platelets by apheresis. People who took warfarin (Coumadin&reg;) are generally not allowed to donate blood for approximately seven days after the last dose. The reason for this is that this blood does not contain sufficient quantities of clotting factor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Laboratory testing of donated blood",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a unit of blood has been donated, the blood is tested in a laboratory for infectious diseases that can be transmitted by blood transfusion. These include tests for HIV, hepatitis B, hepatitis C, human T-lymphotropic virus (HTLV), West Nile virus, syphilis, and, in most areas, Chagas disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/19/16690?source=see_link\">",
"      \"Patient information: West Nile virus infection (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Confidential unit exclusion (CUE)",
"     </span>",
"     &nbsp;&mdash;&nbsp;The confidential unit exclusion (CUE) process allows someone who has donated blood to confidentially indicate that his or her blood should not be given to others. This process protects individuals who feel pressured to donate in the workplace or during community blood drives. Donors are asked to place a bar code sticker on their donation form, indicating if their blood should be used. This is done after the interview, but before donation. Although this procedure was commonly used in the past, most United States blood banks no longer use it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Registry of deferred donors",
"     </span>",
"     &nbsp;&mdash;&nbsp;A registry of deferred donors contains names of individuals who have been disqualified from blood donation in the past. Some donors in the registry have infectious diseases, such as hepatitis B or HIV infection. Theoretically, it is possible that an individual with one of these diseases could have a positive test result at one time but negative test results at a later time.",
"    </p>",
"    <p>",
"     Other donors in the registry have provided information in the past that disqualified them from blood donation. A donor's name is usually checked against this registry before and after donation. The reason for the deferral is not usually available to staff at the collection facility.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Telephone callbacks",
"     </span>",
"     &nbsp;&mdash;&nbsp;After donating blood, donors are given a phone number so that they can call the donation center to report any factors that may affect the use of their blood or to report symptoms of infections in the first days after donating (such as symptoms of upper respiratory tract infection or gastrointestinal illness). Such reports will be evaluated, and the unit of blood may be destroyed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      RISK OF INFECTION FROM A TRANSFUSION",
"     </span>",
"    </p>",
"    <p>",
"     Safety measures, such as improved screening tests, have dramatically reduced the risk of acquiring a viral infection from a blood transfusion. Recent estimates suggest the following risks of developing certain infections after receiving a unit of blood:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       1 in 200,000 to 1 in 360,000 for hepatitis B",
"      </li>",
"      <li>",
"       1 in 1 million to 1 in 2 million for hepatitis C",
"      </li>",
"      <li>",
"       1 in 1.5 million to 1 in 2 million for human immunodeficiency virus (HIV)",
"      </li>",
"      <li>",
"       1 in 2 million for human T-cell",
"       <span class=\"nowrap\">",
"        lymphoma/leukemia",
"       </span>",
"       virus (HTLV)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      AUTOLOGOUS BLOOD DONATION",
"     </span>",
"    </p>",
"    <p>",
"     Autologous blood donation is when a donor donates blood for themselves several days to six weeks ahead of a scheduled surgery, when blood might be needed. Autologous blood donation reduces the risk of most, but not all, infectious complications of blood transfusion.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      POTENTIAL COMPLICATIONS OF BLOOD DONATION",
"     </span>",
"    </p>",
"    <p>",
"     Most people who donate blood do not have any complications that require medical care. The most common complications include bruising or soreness at the needle site and fatigue.",
"    </p>",
"    <p>",
"     A small percentage (2 to 5 percent) of people feel faint",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     pass out before, during, or after donating blood. This is more common the first time a person donates and in people who are younger. Drinking a 16 ounce (473 mL) bottle of water before donating may reduce this risk.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804437880\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13062339\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/52/22338?source=see_link\">",
"      Patient information: Blood donation (giving blood) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=see_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=see_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13062354\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=see_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/19/16690?source=see_link\">",
"      Patient information: West Nile virus infection (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link\">",
"      Blood donor medical history",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link\">",
"      Clinical use of plasma components",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link\">",
"      Compatibility testing",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=see_link\">",
"      Controversial areas in preoperative autologous blood donation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11061?source=see_link\">",
"      Directed (designated) blood donation programs",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37174?source=see_link\">",
"      General principles of home blood transfusion",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=see_link\">",
"      Intraoperative and postoperative blood salvage",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"      Massive blood transfusion",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/index.htm\">",
"      www.nhlbi.nih.gov/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Red Cross",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.redcross.org/\">",
"      www.redcross.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       America's Blood Centers",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americasblood.org/\">",
"      www.americasblood.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       AABB (formerly the American Association of Blood Banks)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aabb.org/\">",
"      www.aabb.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?26/12/26820/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 29, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?26/12/26820?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     AABB Uniform Donor History Questionnaire file://www.aabb.org/resources/donation/questionnaires/Documents/dhq/v1-3/Full-LengthDonorHistoryQuestionnairev1.3.pdf (Accessed on September 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26820/abstract/2\">",
"      Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26820/abstract/3\">",
"      Whittaker S, Carter N, Arnold E, et al. Understanding the meaning of permanent deferral for blood donors. Transfusion 2008; 48:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26820/abstract/4\">",
"      Orton SL, Virvos VJ, Williams AE. Validation of selected donor-screening questions: structure, content, and comprehension. Transfusion 2000; 40:1407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f26_12_26820=[""].join("\n");
var outline_f26_12_26820=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SCREENING MEASURES TO PROTECT THE DONOR",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           APHERESIS DONATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           SCREENING MEASURES TO PROTECT THE RECIPIENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           RISK OF INFECTION FROM A TRANSFUSION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           AUTOLOGOUS BLOOD DONATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           POTENTIAL COMPLICATIONS OF BLOOD DONATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f26_12_26821="Amino acid injection: Drug information";
var content_f26_12_26821=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amino acid injection: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6798101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aminosyn&reg;;",
"     </li>",
"     <li>",
"      Aminosyn&reg; II;",
"     </li>",
"     <li>",
"      Aminosyn&reg;-HBC;",
"     </li>",
"     <li>",
"      Aminosyn&reg;-PF;",
"     </li>",
"     <li>",
"      Aminosyn&reg;-RF;",
"     </li>",
"     <li>",
"      BranchAmin&reg; [DSC];",
"     </li>",
"     <li>",
"      Clinisol&reg;;",
"     </li>",
"     <li>",
"      FreAmine&reg; HBC;",
"     </li>",
"     <li>",
"      FreAmine&reg; III;",
"     </li>",
"     <li>",
"      HepatAmine&reg;;",
"     </li>",
"     <li>",
"      Hepatasol&reg; [DSC];",
"     </li>",
"     <li>",
"      NephrAmine&reg;;",
"     </li>",
"     <li>",
"      PremaSol&trade;;",
"     </li>",
"     <li>",
"      Prosol;",
"     </li>",
"     <li>",
"      Travasol&reg;;",
"     </li>",
"     <li>",
"      TrophAmine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aminosyn;",
"     </li>",
"     <li>",
"      Aminosyn-PF;",
"     </li>",
"     <li>",
"      Aminosyn-RF;",
"     </li>",
"     <li>",
"      Aminosyn&reg; II;",
"     </li>",
"     <li>",
"      Primene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6798102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Intravenous Nutritional Therapy",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6798111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protein as amino acids: I.V. (as a component of parenteral nutrition):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Maintenance:",
"     </b>",
"     0.8-1 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Normal/mild stress level:",
"     </b>",
"     1-1.2 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Moderate stress level:",
"     </b>",
"     1.2-1.5 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Severe stress level:",
"     </b>",
"     1.5-2 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Burn patients (severe):",
"     </b>",
"     Increase protein until significant wound healing achieved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Solid organ transplant:",
"     </b>",
"     Perioperative: 1.5-2 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Renal failure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Acute (severely malnourished or hypercatabolic): 1.5-1.8 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Chronic, with dialysis: 1.2-1.3 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Chronic, without dialysis: 0.6-0.8 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Continuous hemofiltration: &ge;1 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hepatic failure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Acute management when other treatments have failed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     With encephalopathy: 0.6-1 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Without encephalopathy: 1-1.5 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Chronic encephalopathy: Use branch chain amino acid enriched diets only if unresponsive to pharmacotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pregnant women in second or third trimester:",
"     </b>",
"     Add an additional 10-14 g/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6798110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protein as amino acids: I.V. (as a component of parenteral nutrition):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Term:",
"     </b>",
"     Initial: 2.5 g/kg/day; Goal: 3 g/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Extremely (&lt;1000 g) and very (&lt;1500 g) low-birth-weight (stable):",
"     </b>",
"     Initial: 1-1.5 g/kg/day; Goal: 3.5-3.85 g/kg/day to promote utero growth rates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sepsis, hypoxia:",
"     </b>",
"     Initial: 1 g/kg/day; goal: 3-3.85 g/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with severe renal failure. Use with caution in patients with renal insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients in hepatic coma. In patients with hepatic insufficiency, conservative doses should be considered; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F238292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [branched chain]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aminosyn&reg;-HBC: 7% (500 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BranchAmin&reg;: 4% (500 mL [DSC]) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FreAmine&reg; HBC: 6.9% (750 mL) [contains aluminum, sodium bisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [crystalline]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aminosyn&reg;: 8.5% (500 mL); 10% (500 mL, 1000 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aminosyn&reg; II: 8.5% (500 mL); 10% (500 mL, 1000 mL, 2000 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aminosyn&reg; II: 10% (2000 mL [DSC]) [contains aluminum, sodium hydrosulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aminosyn&reg; II: 15% (2000 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clinisol&reg;: 15% (500 mL, 2000 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FreAmine&reg; III: 3% (1000 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FreAmine&reg; III: 8.5% (500 mL); 10% (500 mL, 1000 mL) [contains aluminum, sodium bisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PremaSol&trade;: 6% (500 mL); 10% (500 mL, 1000 mL, 2000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prosol: 20% (2000 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Travasol&reg;: 10% (500 mL, 1000 mL, 2000 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [hepatic]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HepatAmine&reg;: 8% (500 mL) [contains aluminum, sodium bisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatasol&reg;: 8% (500 mL [DSC]) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [pediatric]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aminosyn&reg;-PF: 7% (500 mL); 10% (1000 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TrophAmine&reg;: 6% (500 mL); 10% (500 mL) [contains aluminum, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [renal]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aminosyn&reg;-RF: 5.2% (500 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NephrAmine&reg;: 5.4% (250 mL) [contains aluminum, sodium bisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F238295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administered as a component of peripheral parenteral or total parenteral nutrition. Peripheral administration of nutrition is dependent upon osmolality of solution. Total parenteral nutrition must be administered via central venous access.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F238294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As part of parenteral nutrition to prevent nitrogen loss or treat negative nitrogen balance when alimentary tract cannot be used (eg, GI absorption is impaired, bowel rest is needed). Specialty amino acid formulas may be considered only in certain instances.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7913784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TrophAmine&reg; may be confused with tromethamine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6798106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid, electrolyte imbalance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Erythema, phlebitis, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Azotemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F238297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inborn errors of amino acid metabolism",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F238283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Use with caution in patients sensitive to volume overload (eg, heart failure, hepatic failure); consider concentrated total parenteral nutrition formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in protein delivery especially in patients with hepatic encephalopathy; dosage adjustments may be necessary. Consider volume status in patients with hepatic failure, may require concentrated total parenteral nutrition formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; dosage adjustments may be necessary depending upon renal replacement therapy options. It is essential to provide adequate calories in a minimal amount of fluid.  Monitor fluid balance closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aluminum: Solutions may contain aluminum; toxic levels may occur following prolonged administration in premature neonates or patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfites: Some products contain sulfites as preservatives.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warning/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Monitoring: Monitor fluid and electrolyte status.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F238289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13334400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Animal reproduction studies have not been conducted. Following administration, an increase of some amino acids is observed in the fetus (Ronzoni, 1999; Ronzoni, 2002). In women with hyperemesis gravidarum, parenteral nutrition may be considered for any woman who cannot maintain her weight because of vomiting (ACOG, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6798103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13334401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous amino acids are found in breast milk (IOM, 1991).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Amino Acid Infusion Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (1000 mL): $26.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminosyn II Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7% (500 mL): $13.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.5% (500 mL): $14.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (2000 mL): $38.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (2000 mL): $48.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminosyn II/Electrolytes Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.5% (500 mL): $12.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminosyn Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5% (1000 mL): $12.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7% (500 mL): $14.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.5% (500 mL): $10.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (500 mL): $20.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminosyn M Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5% (1000 mL): $11.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminosyn-HBC Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7% (500 mL): $73.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminosyn-HF Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8% (500 mL): $87.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminosyn-PF Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7% (500 mL): $44.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (1000 mL): $80.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminosyn-RF Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.2% (500 mL): $27.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Clinisol SF Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (500 mL): $86.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (FreAmine HBC Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.9% (750 mL): $78.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (FreAmine III Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (1000 mL): $12.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Freamine III Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.5% (1000 mL): $24.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (1000 mL): $15.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hepatamine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8% (500 mL): $93.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hepatasol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8% (500 mL): $108.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (NephrAmine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.4% (250 mL): $26.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Premasol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6% (500 mL): $39.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (1000 mL): $87.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Prosol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (2000 mL): $107.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Travasol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (1000 mL): $24.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Trophamine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6% (500 mL): $50.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (TrophAmine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (500 mL): $33.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F238290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     General patient monitoring during I.V. nutritional therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bone densitometry: Perform upon initiation of long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Efficacy: Nutrition and outcome parameters should be measured serially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Electrolytes: Sodium, potassium, chloride, and bicarbonate should be monitored frequently upon initiation and until stable; phosphate should be monitored closely in patients with pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose: In patients with diabetes or patients with glucose intolerance risk factors, monitor closely. Monitor frequently upon initiation of therapy and with any changes in insulin dose or renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Line site: Monitor for signs and symptoms of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liver function tests: Monitor periodically.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neonates: Sodium, calcium, and phosphate should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Refeeding syndrome: Patients at risk should have phosphorus, magnesium, potassium, and glucose levels monitored closely at initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Triglycerides: Before initiation of lipid therapy and at least weekly during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vitamin A status: Should be carefully monitored in patients with chronic renal failure.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetrics and Gynecology, \"ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: Nausea and Vomiting of Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 103(4):803-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/12/26821/abstract-text/15051578/pubmed\" id=\"15051578\" target=\"_blank\">",
"        15051578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute of Medicine, Subcommittee on Nutrition During Lactation, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board, National Academy of Sciences, \"Nutrition During Lactation,\" 1991. Available at",
"      <a href=\"file://www.nap.edu/catalog.php?record_id=1577\" target=\"_blank\">",
"       file://www.nap.edu/catalog.php?record_id=1577",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ronzoni S, Marconi AM, Cetin I, et al, \"Umbilical Amino Acid Uptake at Increasing Maternal Amino Acid Concentrations: Effect of a Maternal Amino Acid Infusate,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1999, 181(2):477-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/12/26821/abstract-text/10454703/pubmed\" id=\"10454703\" target=\"_blank\">",
"        10454703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ronzoni S, Marconi AM, Paolini CL, et al, \"The Effect of a Maternal Infusion of Amino Acids on Umbilical Uptake in Pregnancies Complicated by Intrauterine Growth Restriction,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2002, 187(3):741-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/12/26821/abstract-text/12237657/pubmed\" id=\"12237657\" target=\"_blank\">",
"        12237657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9355 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26821=[""].join("\n");
var outline_f26_12_26821=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6798101\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934087\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6798102\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6798111\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6798110\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671603\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671604\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238292\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238295\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238294\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913784\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6798106\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238297\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238283\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238289\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334400\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6798103\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334401\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322824\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238290\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9355\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9355|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_12_26822="Chapter 6G: Calcium and phosphate metabolism in renal failure";
var content_f26_12_26822=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 6G: Calcium and phosphate metabolism in renal failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26822/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26822/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26822/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26822/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26822/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26822/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26822/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/12/26822/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a complete discussion of the abnormalities in mineral metabolism that occur &nbsp;in patients with chronic renal failure is beyond the scope of this chapter, it is useful to review briefly how the homeostatic mechanisms governing calcium and phosphate balance can be impaired in this setting due to alterations in phosphate excretion and in PTH and calcitriol release [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHOSPHATE BALANCE AND SECONDARY HYPERPARATHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal failure is characterized by a decrease in the functioning renal mass and, therefore, in the total glomerular filtration rate (GFR). With the initial fall in GFR, there is a reduction in the filtered phosphate load and consequently in phosphate excretion. If intake remains constant, the net effect will be phosphate retention and a small increase in the plasma phosphate concentration. This mild phosphate retention is intimately related to the common development of secondary hyperparathyroidism. As illustrated in Figure 1 (",
"    <a class=\"graphic graphic_figure graphicRef68602 \" href=\"UTD.htm?28/43/29373\">",
"     figure 1",
"    </a>",
"    ), progressive renal failure is associated with a marked increase in circulating PTH levels that correlates roughly with the degree of decline in GFR. If, however, phosphate retention is prevented by restricting phosphate intake, secondary hyperparathyroidism does not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which phosphate retention leads to hyperparathyroidism is incompletely understood. It was initially thought that excess phosphate will drive the following reaction to the right [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Ca2+ &nbsp;+ &nbsp;HPO42- &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;CaHPO4",
"   </p>",
"   <p>",
"    The ensuing reduction in the plasma Ca2+ concentration can then stimulate the secretion of PTH which, by increasing Ca2+ release from bone and phosphate excretion in the urine, will return both the plasma Ca2+ and phosphate concentrations to normal (",
"    <a class=\"graphic graphic_figure graphicRef56732 \" href=\"UTD.htm?24/46/25325\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, several observations are not compatible with this hypothesis. First, the initial minor degree of hyperphosphatemia may not be sufficient to cause a large enough reduction in the plasma Ca2+ concentration to enhance PTH release [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/7\">",
"     7",
"    </a>",
"    ]. Second, maintenance of normocalcemia by the administration of Ca2+ does not prevent the development of hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternate and not mutually exclusive theory is that phosphate retention acts by diminishing the renal production of calcitriol&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. This will then lead to hyperparathyroidism both by lowering the plasma Ca2+ concentration and by removing the inhibitory effect of calcitriol on PTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The following observations are compatible with this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma calcitriol levels are often reduced in patients with mild to moderate renal insufficiency, not elevated as would be expected from the presence of hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Even the finding of normal or near normal calcitriol levels does not necessarily preclude a role for initial calcitriol deficiency, since the secondary hyperparathyroidism will increase calcitriol synthesis.",
"     </li>",
"     <li>",
"      The institution of dietary phosphate restriction is able to reverse many of the abnormalities in mineral metabolism: the plasma level of calcitriol is increased, while that of PTH is diminished [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]; and intestinal Ca2+ absorption is markedly improved [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/13\">",
"       13",
"      </a>",
"      ]. In advanced renal failure, the decline in PTH secretion can occur without change in the plasma levels of calcitriol (presumably due to the marked reduction in functioning renal mass) or of Ca2+. This observation suggests that hyperphosphatemia itself may contribute to the hyperparathyroidism, a theory that has been confirmed in both experimental and humans studies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of calcitriol to normalize the plasma calcitriol can prevent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/8\">",
"       8",
"      </a>",
"      ] or reverse secondary hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/10,18\">",
"       10,18",
"      </a>",
"      ], an effect that cannot be achieved by raising the plasma Ca2+ concentration with Ca2+ supplementation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/8,10\">",
"       8,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Partial resistance to the action of calcitriol also may play an important role in the pathogenesis of hyperparathyroidism. In particular, normal concentrations of calcitriol may be unable to suppress PTH secretion, perhaps due to a decreased number of calcitriol receptors in the parathyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/19\">",
"     19",
"    </a>",
"    ]. This change can be demonstrated relatively early (when the plasma creatinine concentration has only doubled) in experimental animals; at a later stage, retained uremic toxins may contribute by decreasing both receptor synthesis and hormone-receptor function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This defect may also explain why supraphysiologic levels of calcitriol (via intravenous or intraperitoneal administration) can markedly diminish PTH release in patients on maintenance dialysis, while physiologic oral doses are relatively ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/10,22,23\">",
"     10,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the exact mechanism, the hypersecretion of PTH is initially appropriate, since it tends to normalize both the plasma Ca2+ and phosphate concentrations. This effect is not complete as some patients may have a mild elevation in the plasma phosphate concentration of less than 1",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    this minor degree of hyperphosphatemia may be sufficient to cause the persistent impairment in calcitriol release and therefore the continued drive to PTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, each succeeding decrement in GFR will enhance the tendency toward phosphate retention, thereby requiring a further rise in PTH release (",
"    <a class=\"graphic graphic_figure graphicRef56732 \" href=\"UTD.htm?24/46/25325\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Maladaptive effects of hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the long-term, however, the development of hyperparathyroidism is in part",
"    <strong>",
"     maladaptive",
"    </strong>",
"    , because chronic exposure to high levels of PTH can lead to potentially serious bone disease, called osteitis fibrosa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Furthermore, PTH loses its ability to maintain normophosphatemia when the GFR falls below 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Because of the inhibitory effect of PTH on proximal phosphate reabsorption, the fraction of the filtered phosphate that is reabsorbed can fall from the normal value of 80 to 95 percent to as low as 15 percent in severe renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/24\">",
"     24",
"    </a>",
"    ]. At this point, PTH is unable to further increase phosphate excretion but continues to promote phosphate release from bone, resulting in persistent hyperphosphatemia if intake is not diminished. This may lead to the development of a vicious cycle since, as noted above, hyperphosphatemia in advanced renal failure can directly stimulate further PTH release [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of marked hyperphosphatemia and a normal or low-normal plasma Ca2+ concentration will result in a very high calcium-phosphate product and a tendency for calcium phosphate precipitation into arteries, joints, soft tissues, and the viscera; this process is called",
"    <strong>",
"     metastatic calcification",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/25\">",
"     25",
"    </a>",
"    ]. Total parathyroidectomy (usually with autotransplantation of some parathyroid tissue into the forearm) may be performed in this setting, since it will lower PTH levels as well as the plasma calcium and phosphate concentrations (",
"    <a class=\"graphic graphic_figure graphicRef72139 \" href=\"UTD.htm?17/35/17982\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The latter changes are due to diminished bone resorption and to the deposition of calcium phosphate in bones previously demineralized by chronic hyperparathyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREVENTION OF SECONDARY HYPERPARATHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the deleterious consequences of prolonged hypersecretion of PTH, a variety of modalities have been tried in an attempt to prevent this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oral phosphate binders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most obvious is limiting net phosphate absorption. Dietary restriction can be attempted, but compliance is often a major problem. Furthermore, urinary phosphate excretion falls to such low levels in end-stage renal disease that limiting intake is not sufficient to prevent phosphate accumulation. In this setting, phosphate balance can be maintained only by binding dietary phosphate in the intestine using a phosphate binder such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]&dagger;. This will lead to the formation of insoluble calcium phosphate precipitates in the gut and decreased intestinal phosphate absorption. Absorption of some of this calcium can also raise the plasma Ca2+ concentration, which may further lower PTH levels.",
"   </p>",
"   <p>",
"    &nbsp;&dagger; Aluminum containing antacids had been widely used but created a &nbsp;major new problem:",
"    <strong>",
"     aluminum intoxication",
"    </strong>",
"    due to the gradual tissue accumulation of absorbed aluminum, particularly in bone and the brain. The clinical manifestations of this syndrome include osteomalacia, bone and muscle pain, microcytic anemia, and in selected cases dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/33\">",
"     33",
"    </a>",
"    ]. There is no safe dose that is also effective as a phosphate binder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"     Calcium citrate",
"    </a>",
"    has also been used; however, this preparation is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in renal failure since citrate can markedly increase intestinal aluminum absorption and predispose to aluminum toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]. Citrate appears to act in two ways: it combines with aluminum to form the soluble and absorbable aluminum citrate salt; and it complexes with intestinal calcium. The ensuing decrease in free calcium then leads to increased permeability of the tight junctions between the cells, a change that can markedly enhance passive aluminum absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/35\">",
"     35",
"    </a>",
"    ]. Similar considerations apply to the concurrent administration of aluminum with sodium citrate (Bicitra&trade;), which has been used to treat uremic acidosis.",
"   </p>",
"   <p>",
"    The main problem with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"     calcium acetate",
"    </a>",
"    therapy is that hypercalcemia is a not infrequent complication with this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. As a result, close monitoring is essential particularly in patients also being treated with a vitamin D metabolite such as calcitriol&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/31\">",
"     31",
"    </a>",
"    ]. An aluminum-containing antacid or preferably sevelamer (RenaGel, see below) can be added if hyperphosphatemia persists or hypercalcemia limits the use of calcium.",
"   </p>",
"   <p>",
"    Any phosphate binder should be",
"    <strong>",
"     given with meals",
"    </strong>",
"    to impair the absorption of dietary phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/36\">",
"     36",
"    </a>",
"    ]. Administration between meals, in comparison, only binds the phosphate in intestinal secretions, leading to a much lesser inhibition of net phosphate uptake. The increased binding of calcium or aluminum to phosphate has a second advantage in that cation absorption is also impaired. As a result, the risks of both hypercalcemia and aluminum intoxication are reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The problems with phosphate binders containing calcium, aluminum, or magnesium has led to the search for different compounds that could bind phosphate. One such compound is the nonabsorbable agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    (RenaGel) that contains neither calcium nor aluminum. It is a cationic polymer that binds phosphate through ion exchange. It is as effective as calcium antacids but, because of its expense, is currently used primarily in patients who develop hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Calcitriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of calcitriol deficiency is another important component of therapy in patients with hyperparathyroidism. In patients already on dialysis, for example, the intravenous or intraperitoneal administration of calcitriol can lead to a marked suppression in PTH release [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/10,22,23\">",
"     10,22,23",
"    </a>",
"    ] and improvement in PTH-induced osteitis fibrosa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/23,40\">",
"     23,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcitriol should",
"    <strong>",
"     not",
"    </strong>",
"    be given unless the plasma phosphate concentration has been controlled, since the calcitriol-induced increase in intestinal phosphate absorption can exacerbate underlying hyperphosphatemia. Careful monitoring is also required for the development of hypercalcemia. The risk of hypercalcemia may be circumvented in the future by the administration of synthetic vitamin D analogs (such as 22-oxacalcitriol, 1-alpha-hydroxyvitamin D2, or 19-nor) that have no or less calcemic or phosphatemic effect but are still able to suppress PTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. The factors responsible for the selective actions of these analogs is incompletely understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Correction of metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another factor that may be beneficial is correction of the metabolic acidosis that commonly accompanies chronic renal failure. Buffering of the excess acid in bone leads to loss of bone mineral, possibly contributing to the development of hyperparathyroid bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26822/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42947?source=see_link\">",
"     \"Chapter 6H: Catecholamines and the kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/1\">",
"      Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/2\">",
"      Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38:193.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Henrich, WL. Pathogenesis of renal osteodystrophy. In: UpToDate in Medicine, Rose, BD (Ed), UpToDate, Wellesley, MA, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/4\">",
"      Slatopolsky E, Bricker NS. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 1973; 4:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/5\">",
"      Rutherford WE, Bordier P, Marie P, et al. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest 1977; 60:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/6\">",
"      Hebert LA, Lemann J Jr, Petersen JR, Lennon EJ. Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 1966; 45:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/7\">",
"      Adler AJ, Ferran N, Berlyne GM. Effect of inorganic phosphate on serum ionized calcium concentration in vitro: a reassessment of the \"trade-off hypothesis\". Kidney Int 1985; 28:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/8\">",
"      Lopez-Hilker S, Galceran T, Chan YL, et al. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 1986; 78:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/9\">",
"      Slatopolsky E, Lopez-Hilker S, Delmez J, et al. The parathyroid-calcitriol axis in health and chronic renal failure. Kidney Int Suppl 1990; 29:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/10\">",
"      Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/11\">",
"      Koenig KG, Lindberg JS, Zerwekh JE, et al. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int 1992; 41:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/12\">",
"      Prince RL, Hutchison BG, Kent JC, et al. Calcitriol deficiency with retained synthetic reserve in chronic renal failure. Kidney Int 1988; 33:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/13\">",
"      Llach F, Massry SG. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 1985; 61:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/14\">",
"      Portale AA, Booth BE, Halloran BP, Morris RC Jr. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/15\">",
"      Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/16\">",
"      Fine A, Cox D, Fontaine B. Elevation of serum phosphate affects parathyroid hormone levels in only 50% of hemodialysis patients, which is unrelated to changes in serum calcium. J Am Soc Nephrol 1993; 3:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/17\">",
"      Almaden Y, Hernandez A, Torregrosa V, et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998; 9:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/18\">",
"      Quarles LD, Davidai GA, Schwab SJ, et al. Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/19\">",
"      Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/20\">",
"      Hsu CH, Patel SR, Vanholder R. Mechanism of decreased intestinal calcitriol receptor concentration in renal failure. Am J Physiol 1993; 264:F662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/21\">",
"      Hsu CH, Patel SR, Young EW, Vanholder R. The biological action of calcitriol in renal failure. Kidney Int 1994; 46:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/22\">",
"      Delmez JA, Dougan CS, Gearing BK, et al. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 1987; 31:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/23\">",
"      Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/24\">",
"      Slatopolsky E, Robson AM, Elkan I, Bricker NS. Control of phosphate excretion in uremic man. J Clin Invest 1968; 47:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/25\">",
"      Katz AI, Hampers CL, Merrill JP. Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Analysis of 195 patients, with observations on the effects of chronic dialysis, kidney transplantation and subtotal parathyroidectomy. Medicine (Baltimore) 1969; 48:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/26\">",
"      Llach F. Parathyroidectomy in chronic renal failure: indications, surgical approach and the use of calcitriol. Kidney Int Suppl 1990; 29:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/27\">",
"      Gagn&eacute; ER, Ure&ntilde;a P, Leite-Silva S, et al. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992; 3:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/28\">",
"      Stracke S, Jehle PM, Sturm D, et al. Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis 1999; 33:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/29\">",
"      Fournier A, Morini&egrave;re P, Ben Hamida F, et al. Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney Int Suppl 1992; 38:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/30\">",
"      Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/31\">",
"      Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992; 3:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/32\">",
"      Mai ML, Emmett M, Sheikh MS, et al. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/33\">",
"      Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 1987; 31:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/34\">",
"      Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/35\">",
"      Molitoris BA, Froment DH, Mackenzie TA, et al. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int 1989; 36:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/36\">",
"      Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989; 320:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/37\">",
"      Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999; 55:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/38\">",
"      Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/39\">",
"      Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/40\">",
"      Coburn JW. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int Suppl 1990; 38:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/41\">",
"      Slatopolsky E, Berkoben M, Kelber J, et al. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int Suppl 1992; 38:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/42\">",
"      Finch JL, Brown AJ, Kubodera N, et al. Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 1993; 43:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/43\">",
"      Tan AU Jr, Levine BS, Mazess RB, et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/44\">",
"      Monier-Faugere MC, Geng Z, Friedler RM, et al. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999; 55:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/45\">",
"      Martin KJ, Gonz&aacute;lez EA, Gellens M, et al. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26822/abstract/46\">",
"      Lefebvre A, de Vernejoul MC, Gueris J, et al. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989; 36:1112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7268 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26822=[""].join("\n");
var outline_f26_12_26822=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHOSPHATE BALANCE AND SECONDARY HYPERPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Maladaptive effects of hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREVENTION OF SECONDARY HYPERPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oral phosphate binders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Calcitriol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Correction of metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7268\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7268|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/43/29373\" title=\"figure 1\">",
"      Relationship between GFR and PTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/46/25325\" title=\"figure 2\">",
"      PO4 induces hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/35/17982\" title=\"figure 3\">",
"      Effects of parathyroidectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42947?source=related_link\">",
"      Chapter 6H: Catecholamines and the kidney",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_12_26823="Increased pulse pressure";
var content_f26_12_26823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Increased pulse pressure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26823/contributors\">",
"     Raymond R Townsend, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26823/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26823/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26823/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/12/26823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical blood pressure measurements include a systolic and diastolic value, which represent the extremes of pressure fluctuation within the circulation during the cardiac cycle. There has been much debate about which increased value alone, either systolic or diastolic hypertension, is more predictive of adverse cardiovascular outcomes in various patient populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mean arterial pressure measurements, which provide another indication of overall circulatory pressure load, have also been proposed as predictive for adverse cardiovascular outcomes. This is either determined directly by catheterization or can be estimated by formulas (such as diastolic blood pressure +",
"    <span class=\"nowrap\">",
"     1/3",
"    </span>",
"    x [systolic pressure &ndash; diastolic pressure]). However, the mean arterial pressure provides less discriminatory power as patients age. The diastolic pressure peaks at and subsequently declines after age 55 years, while the systolic pressure rises relentlessly with each decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, depending upon the respective changes in systolic and diastolic pressures with older age, the mean blood pressure may actually tend to change less as individuals age.",
"   </p>",
"   <p>",
"    Since the diastolic pressure in a population rises until the sixth decade and then subsequently declines with increasing age, an elevation in the diastolic pressure alone is less useful as an outcome predictor in older patients. Increasing emphasis has therefore been placed upon systolic pressure alone as the most useful predictor of cardiovascular disease in these individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several guidelines have supported the use of systolic blood pressure (such as JNC-7) and strongly encourage the use of systolic blood pressure goals in antihypertensive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also an enhanced risk for cardiovascular events associated with increases in pulse pressure (defined below). This topic review will discuss the factors that determine pulse pressure and will present some of the evidence for and against the suggestion that there is an independent link between an increased pulse pressure and adverse cardiovascular outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulse pressure is",
"    <strong>",
"     defined",
"    </strong>",
"    as the systolic minus the diastolic pressure. This value appears, at least in some epidemiologic studies, to be superior in predictive value to the systolic or diastolic values alone (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Increased pulse pressure and adverse outcomes'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    However, given the predictive information from the systolic and diastolic pressures, it is unclear, at first glance, that the pulse pressure provides additional independent information. Among patients with a diastolic pressure of 95 mmHg, for example, a higher pulse pressure simply means that there is a higher systolic pressure which itself is a risk factor for worse outcomes. The pulse pressure also must be considered in the context of the absolute values of systolic and diastolic pressures (eg, a blood pressure of",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg is not equivalent in risk to",
"    <span class=\"nowrap\">",
"     160/120",
"    </span>",
"    mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pulse pressure and age",
"    </span>",
"    &nbsp;&mdash;&nbsp;To better understand the purported associations among pulse pressure, systolic pressure, diastolic pressure, risk of cardiovascular disease, and increasing age, it is worthwhile to review age-related changes in blood pressure measurements and the risk for cardiovascular disease as individuals age.",
"   </p>",
"   <p>",
"    In patients less than 55 years of age, the diastolic and systolic blood pressures are both predictive of adverse events from cardiovascular disease. However, because the diastolic blood pressure declines on average after the age of 55, its predictive value is diminished in older patients.",
"   </p>",
"   <p>",
"    By comparison, the systolic pressure continues to rise with every decade of life, resulting in the maintenance of its predictive value for cardiovascular disease. Thus, in older patients, the association between an increased systolic pressure alone and cardiovascular disease becomes much stronger than that observed with the diastolic blood pressure alone.",
"   </p>",
"   <p>",
"    With increasing age, the pulse pressure correlates more closely with the systolic pressure than with the diastolic pressure, and is therefore also a good predictor of cardiovascular disease among the elderly. An additional benefit of the pulse pressure is that it incorporates both the systolic pressure increase and the diastolic decrease that is observed with age. In some cases, this measurement has superior predictive power to that observed with the systolic pressure alone. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Increased pulse pressure and adverse outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FACTORS RESULTING IN INCREASED PULSE PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increases in the pulse pressure result from factors that increase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decrease the systolic and diastolic pressure, respectively. Since the changes in pulse pressure are mostly related to changes in systolic blood pressure, factors affecting systolic pressure are reviewed first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Increases in systolic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in systolic pressure, particularly among the elderly, are usually the result of stiffness in the large arteries as well as an early pulse wave reflection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Although increases in peripheral vascular resistance appear to be a relatively more important component of hypertension in younger patients (30 to 49 years old), the role of peripheral vascular resistance in hypertension diminishes progressively with age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Given the known effects of aging on vessel stiffness, increases in pulse pressure in older patients (eg, &gt;55 years of age) result from aortic stiffening, while increases in younger patients (ie, &lt;45 years of age) are more likely to result from increases in stroke volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Isolated Systolic Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Decreases in diastolic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since stiffening of the aorta with age reduces the elastic reservoir capacity, more blood runs off from each stroke volume during systole, resulting in a reduced blood volume within the aorta at the onset of diastole. This factor, when combined with diminished elastic recoil and an increased pressure decay rate, causes a fall in the diastolic pressure with age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/7\">",
"     7",
"    </a>",
"    ]. These changes in diastolic pressure (both in normotensive and hypertensive patients) become evident after age 55 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased pulse pressure may be a heritable trait [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. As an example, a genome-wide association study that included more than 120,000 individuals of European ancestry found five loci that were significantly associated with pulse pressure, including three that had opposite effects on systolic and diastolic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/9\">",
"     9",
"    </a>",
"    ]. One of these five loci, the fidgetin gene, was also associated with pulse pressure in an Asian cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/8\">",
"     8",
"    </a>",
"    ]. Other genetic studies have found a high degree of heritability (ranging from 20 to 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] with linkage to chromosome 18 in all ethnic groups, chromosome 19 in whites, and chromosome 17 in Hispanics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since a portion of the systolic pressure depends on the height of the patient, shorter patients tend to have a higher pulse pressure. In addition, slower heart rates result in a greater pulse pressure.",
"   </p>",
"   <p>",
"    In general, women are shorter than men but tend to have faster heart rates. As a result, differences in pulse pressure with gender are generally lacking since the effect of height on pulse pressure may be counter-balanced by the effect of heart rate.",
"   </p>",
"   <p>",
"    Increasing evidence suggests that patients with metabolic syndrome have stiffer vessels, resulting in an increased pulse pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is generally thought that the aorta increases in size with age, some studies suggest that increases in pulse pressure are associated with reductions, not increases, in aortic diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/14\">",
"     14",
"    </a>",
"    ]. In one study of more than a thousand non-diabetic individuals who were free of cardiac disease, aortic root diameter determined by echocardiography was inversely related to pulse pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/14\">",
"     14",
"    </a>",
"    ]. These data suggest that aortic dimensions may contribute to, rather than result from, increased pulse pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INCREASED PULSE PRESSURE AND ADVERSE OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in the pulse pressure places greater stress on arteries, resulting in fatigue and an increased fracture rate in the elastic components of the vessel wall. The vascular intima becomes prone to damage, thereby increasing the risk of atherosclerosis and thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53450682\">",
"    <span class=\"h2\">",
"     Pulse pressure and cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to damage to the vascular wall, an increased pulse pressure is associated with increased stress on the left ventricle, which can result in ventricular hypertrophy and failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/15\">",
"     15",
"    </a>",
"    ]. Heightened pressure during systole increases myocardial oxygen need, and the lower diastolic value may become a limiting factor for coronary perfusion, resulting in ischemia.",
"   </p>",
"   <p>",
"    The net result of these combined effects is that increases in pulse pressure may be a predictor of a variety of adverse cardiovascular outcomes. This association has been observed in numerous population based cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/3,16-24\">",
"     3,16-24",
"    </a>",
"    ], as well as in randomized trials of hypertension treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies illustrate the range of findings from population based cohorts, several of which included individuals with and without hypertension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Framingham Heart Study, for example, each 10 mmHg increment in pulse pressure was associated with a 23 percent higher risk of developing coronary heart disease (",
"      <a class=\"graphic graphic_figure graphicRef74090 \" href=\"UTD.htm?5/50/5934\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/16\">",
"       16",
"      </a>",
"      ]. This association with pulse pressure was primarily seen in patients over age 50, particularly over age 60 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/17\">",
"       17",
"      </a>",
"      ]. The adverse outcomes observed with an elevated pulse pressure in patients over age 50 appear to apply to both normotensive and hypertensive patients, including those with low diastolic but normal systolic blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The association between pulse pressure and cardiovascular mortality was analyzed in over 340,000 men in the MRFIT trial aged 35 to 57 years without pre-existing diabetes or coronary heart disease followed for 22 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/19\">",
"       19",
"      </a>",
"      ]. Systolic and diastolic pressures were stronger predictors of cardiovascular death than pulse pressure. However, pulse pressure was independently associated with risk, particularly among older men (aged 45 to 57 years). Among men younger than 45 years, pulse pressure was associated with mortality only in those with hypertension; among older men, pulse pressure was associated with an increased risk of death at any level of blood pressure. As an example, there was a 22 percent increased risk of cardiovascular mortality in the highest compared with lowest quartile of pulse pressure in men aged 45 years or older who had optimal blood pressure (defined as less than",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg).",
"     </li>",
"     <li>",
"      Other studies, such as the second National Health and Nutrition Examination Survey (NHANES), found that pulse pressure added little predictive value compared with either systolic or diastolic pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/3\">",
"       3",
"      </a>",
"      ]. Among 7830 individuals followed for 15 years, a higher pulse pressure was associated with either increased, decreased, or no change in the risk of cardiovascular and all-cause mortality depending upon age, systolic, and diastolic pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An association between pulse pressure and cardiovascular endpoints has also been observed in hypertension treatment trials, as illustrated by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SHEP trial of elderly patients with isolated systolic hypertension, each 10 mmHg elevation in pulse pressure in the active treatment group was associated with increases in the risk for heart failure or stroke by 32 and 24 percent, respectively, after controlling for systolic pressure and other known risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/25\">",
"       25",
"      </a>",
"      ]. However, pulse pressure was",
"      <strong>",
"       not",
"      </strong>",
"      associated with risk in patients assigned to placebo.",
"     </li>",
"     <li>",
"      Twenty-four hour ambulatory blood pressure recordings were obtained in the Syst-Eur trial, also of older patients with isolated systolic hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/26\">",
"       26",
"      </a>",
"      ]. In the placebo group, the ambulatory pulse pressure predicted all cardiovascular end points and stroke, as each 10 mmHg increase in pulse pressure was associated with a hazard ratio ranging from 1.25 to 1.68. In contrast to the finding from the SHEP trial, this relation was",
"      <strong>",
"       not",
"      </strong>",
"      significant in patients assigned active treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53450556\">",
"    <span class=\"h2\">",
"     Pulse pressure and diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between pulse pressure and the incidence of type 2 diabetes was examined in 2685 initially nondiabetic patients aged 20 to 84 years enrolled in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     Candesartan",
"    </a>",
"    Antihypertensive Survival Evaluation in Japan (CASE-J) trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/27\">",
"     27",
"    </a>",
"    ]. Higher pulse pressure was significantly associated with an increased risk of developing diabetes (relative risk 1.44 for each 16 mmHg higher pulse pressure, 95% CI 1.15-1.79). Similarly, the pulse pressure divided by the mean arterial pressure, as a measure of vascular stiffness, was directly associated with diabetes risk. The mechanism underlying this association is unclear.",
"   </p>",
"   <p>",
"    Consistent findings were observed in a cross-sectional study of 528 hypertensive patients from Italy who had both clinic and 24 hour ambulatory blood pressure measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/13\">",
"     13",
"    </a>",
"    ]. Clinic pulse pressure was significantly higher in patients with the metabolic syndrome compared with patients without the metabolic syndrome (61 versus 49 mmHg); results were similar for 24 hour ambulatory pulse pressure. Higher pulse pressure was also associated with individual components of the metabolic syndrome, including higher fasting serum glucose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53450570\">",
"    <span class=\"h2\">",
"     Pulse pressure and progression of chronic kidney disease (CKD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulse pressure, as a reflection of arterial stiffness, may be an independent risk factor for progression of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. The following studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The association between blood pressure components and risk of end-stage renal disease (ESRD) was analyzed among 1513 patients with diabetic nephropathy in a post-hoc analysis of the RENAAL trial [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/30\">",
"       30",
"      </a>",
"      ]. After controlling for multiple potential confounders, a 10 mmHg higher pulse pressure was significantly associated with a 17 percent higher relative risk of developing ESRD. A similar association was found for systolic but not diastolic pressure.",
"     </li>",
"     <li>",
"      Among 329 patients with CKD (mean estimated glomerular filtration rate of 39",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2), a 10 mmHg higher pulse pressure was significantly associated with a 10 percent greater relative risk of kidney function decline after approximately six months of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PULSE PRESSURE AND ANTIHYPERTENSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that antihypertensive agents differ in their effects on pulse pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       Losartan",
"      </a>",
"      Intervention For Endpoints trial (LIFE) comparing an ARB (losartan) to a beta-blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      ), the risk of the composite endpoint (stroke, MI and CV death) rose significantly as pulse pressure increased in the atenolol group [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/33\">",
"       33",
"      </a>",
"      ]. In the losartan group, the risk of the composite endpoint also rose across the pulse pressure quartiles, but the increase was not significant.",
"     </li>",
"     <li>",
"      In a retrospective analysis of a VA Cooperative hypertensive trial including 1292 men with a diastolic blood pressure of 95 to 109 mm Hg at randomization, after one year of treatment,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      reduced pulse pressure by 8.6 mm Hg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      by 6.3 mm Hg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      by 5.5 mm Hg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      by 5 mm Hg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      by 4.1 mm Hg, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      by 4.1 mm Hg [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a substudy of the ASCOT trial (Conduit Artery Functional Evaluation [CAF&Eacute;]), 2073 participants underwent radial artery applanation tonometry and measurement of pulse wave velocity to calculate pulse pressure and central blood pressures [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/35-38\">",
"       35-38",
"      </a>",
"      ]. The results suggested that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      had less central blood pressure reduction and improvement in pulse pressure, despite similar typical brachial artery blood pressure reduction, than a calcium channel blocker regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. Central pulse pressure was also associated with clinical outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of data from clinical trials including more than 28,000 subjects suggested that the cardiovascular benefit of antihypertensive therapy was mostly linked to systolic blood pressure control [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/39\">",
"       39",
"      </a>",
"      ]. In addition, the reduction in systolic pressure with treatment was found to be progressively larger than the reduction in diastolic blood pressure with increasing age (eg, greater fall in pulse pressure with increasing age) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the REASON trial, patients randomly assigned to the",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"        perindopril",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35846?source=see_link\">",
"        indapamide",
"       </a>",
"      </span>",
"      regimen showed greater pulse pressure decreases with treatment when metabolic syndrome was present (10 to 11 mm Hg) than when metabolic syndrome was absent (2 to 3 mm Hg) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a post hoc analysis of the CALM II trial, which compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      40 mg to lisinopril 20 mg plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      16 mg daily in hypertensive diabetics, combination therapy produced a greater reduction in the pulse pressure compared to lisinopril alone as determined by ambulatory blood pressure monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/42\">",
"       42",
"      </a>",
"      ]. The differences in pulse pressure were principally due to greater reductions in systolic pressure in the combination group. This study was not powered to assess outcome differences [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/42\">",
"       42",
"      </a>",
"      ]. Further discussion of the CALM II trial can be found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\"",
"      </a>",
"      .).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is premature to use pulse pressure, however, as a factor in deciding which antihypertensive agent to employ or to use the measurement as a treatment end point itself [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/43\">",
"     43",
"    </a>",
"    ]. Further prospective research is required to define pulse pressure as a predictor of cardiovascular outcomes, and to determine whether pulse pressure is a better index of response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The pulse pressure probably best serves as a tool in clinical trials, to better illustrate the pharmacodynamic effects of drugs, and possibly to provide a sharpened estimate of overall cardiovascular disease risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONCLUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature appears to be divided on the prognostic values of the four measures of blood pressure: systolic, diastolic, mean, and pulse pressures. This arises in part because they are, basically, related to one another as they are all measures of the response in the circulation to each heartbeat. The value of one measure over another is strongly age dependent, and is also related to how variables are entered into statistical models that help predict cardiovascular outcomes.",
"   </p>",
"   <p>",
"    The best use of pulse pressure at this time appears to be in providing help in revising the risk estimate of the systolic pressure in older individuals. Since systolic pressure predicts cardiovascular morbidity and mortality in older patients, clinicians are encouraged to revise upward the estimate of cardiovascular risk in older patients when the pulse pressure is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/46\">",
"     46",
"    </a>",
"    ]. A reasonable summation of our knowledge is that diastolic blood pressure is the best predictor of cardiovascular disease risk in the young (&lt;50 years), all three blood pressure components are equally predictive at ages 50 to 59 years, and pulse pressure is the best predictor from age 60 years and beyond.",
"   </p>",
"   <p>",
"    Limited data also suggest that antihypertensive agents differ in their effects on pulse pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/32\">",
"     32",
"    </a>",
"    ]. However, it is premature to use pulse pressure as a factor in deciding which antihypertensive agent to employ or to use the measurement as a treatment end point itself [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26823/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulse pressure is",
"      <strong>",
"       defined",
"      </strong>",
"      as the systolic minus the diastolic pressure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical perspective'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased pulse pressure may be due to either or both an increase in systolic or a decrease in diastolic blood pressures. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Factors resulting in increased pulse pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among older patients, increased systolic pressure results from increased stiffness in the aorta and other large arteries; among younger patients, increased stroke volume plays a more important role. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Increases in systolic pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased diastolic pressure results from a reduction in aortic blood volume at the onset of diastole. This is related to the age-related decrease in elasticity of the aorta which causes more blood to run off during systole. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Decreases in diastolic pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pulse pressure is a good predictor of cardiovascular events among elderly patients and in some cases has superior predictive capability to that provided by systolic pressure alone. The best use of pulse pressure is in revising upward the risk estimate provided by the systolic pressure in older individuals. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Increased pulse pressure and adverse outcomes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Conclusions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited data suggest that different hypertensive agents may have varying effects on pulse pressure. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pulse pressure and antihypertensive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/1\">",
"      Franklin SS, Gustin W 4th, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/2\">",
"      Chobaninan, AV, Bakris, GL, Black, HR, et al. National Heart, lung and blood institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressure; National high blood pressure education program coordinating committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, the JNC 7 report. JAMA 2003; 21:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/3\">",
"      Pastor-Barriuso R, Banegas JR, Dami&aacute;n J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/4\">",
"      Nichols WW, Nicolini FA, Pepine CJ. Determinants of isolated systolic hypertension in the elderly. J Hypertens Suppl 1992; 10:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/5\">",
"      O'Rourke MF, Nichols WW. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 2005; 45:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/6\">",
"      Messerli FH, Sundgaard-Riise K, Ventura HO, et al. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983; 2:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/7\">",
"      Folkow B. Structure and function of the arteries in hypertension. Am Heart J 1987; 114:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/8\">",
"      Kato N, Takeuchi F, Tabara Y, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet 2011; 43:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/9\">",
"      Wain LV, Verwoert GC, O'Reilly PF, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet 2011; 43:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/10\">",
"      Bielinski SJ, Lynch AI, Miller MB, et al. Genome-wide linkage analysis for loci affecting pulse pressure: the Family Blood Pressure Program. Hypertension 2005; 46:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/11\">",
"      Hsu FC, Zaccaro DJ, Lange LA, et al. The impact of pedigree structure on heritability estimates for pulse pressure in three studies. Hum Hered 2005; 60:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/12\">",
"      Pettersson-Fernholm K, Fr&ouml;jd&ouml; S, Fagerudd J, et al. The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients. Kidney Int 2006; 69:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/13\">",
"      Mul&egrave; G, Nardi E, Cottone S, et al. Relationship of metabolic syndrome with pulse pressure in patients with essential hypertension. Am J Hypertens 2007; 20:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/14\">",
"      Farasat SM, Morrell CH, Scuteri A, et al. Pulse pressure is inversely related to aortic root diameter implications for the pathogenesis of systolic hypertension. Hypertension 2008; 51:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/15\">",
"      O'Rourke M, Frohlich ED. Pulse pressure: Is this a clinically useful risk factor? Hypertension 1999; 34:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/16\">",
"      Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999; 100:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/17\">",
"      Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/18\">",
"      Thomas F, Blacher J, Benetos A, et al. Cardiovascular risk as defined in the 2003 European blood pressure classification: the assessment of an additional predictive value of pulse pressure on mortality. J Hypertens 2008; 26:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/19\">",
"      Domanski M, Mitchell G, Pfeffer M, et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002; 287:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/20\">",
"      Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation 2009; 119:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/21\">",
"      Lorenzo C, Aung K, Stern MP, Haffner SM. Pulse pressure, prehypertension, and mortality: the San Antonio heart study. Am J Hypertens 2009; 22:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/22\">",
"      Okada K, Iso H, Cui R, et al. Pulse pressure is an independent risk factor for stroke among middle-aged Japanese with normal systolic blood pressure: the JPHC study. J Hypertens 2011; 29:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/23\">",
"      Panagiotakos DB, Kromhout D, Menotti A, et al. The relation between pulse pressure and cardiovascular mortality in 12,763 middle-aged men from various parts of the world: a 25-year follow-up of the seven countries study. Arch Intern Med 2005; 165:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/24\">",
"      Assmann G, Cullen P, Evers T, et al. Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. Eur Heart J 2005; 26:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/25\">",
"      Vaccarino V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol 2001; 88:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/26\">",
"      Staessen JA, Thijs L, O'Brien ET, et al. Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens 2002; 15:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/27\">",
"      Yasuno S, Ueshima K, Oba K, et al. Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Diabetes Care 2010; 33:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/28\">",
"      Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010; 55:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/29\">",
"      Arulkumaran N, Diwakar R, Tahir Z, et al. Pulse pressure and progression of chronic kidney disease. J Nephrol 2010; 23:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/30\">",
"      Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/31\">",
"      Tanaka M, Babazono T, Takeda M, Iwamoto Y. Pulse pressure and chronic kidney disease in patients with type 2 diabetes. Hypertens Res 2006; 29:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/32\">",
"      Domanski MJ, Davis BR, Pfeffer MA, et al. Isolated systolic hypertension : prognostic information provided by pulse pressure. Hypertension 1999; 34:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/33\">",
"      Fyhrquist F, Dahl&ouml;f B, Devereux RB, et al. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension 2005; 45:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/34\">",
"      Cushman WC, Materson BJ, Williams DW, Reda DJ. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension 2001; 38:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/35\">",
"      Williams B, O'Rourke M, Anglo-Scandinavian Cardiac Outcomes Trial. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens 2001; 15 Suppl 1:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/36\">",
"      Katakam R, Townsend RR. What's in a pulse? J Clin Hypertens (Greenwich) 2006; 8:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/37\">",
"      Dahl&ouml;f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/38\">",
"      Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/39\">",
"      Wang JG, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005; 45:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/40\">",
"      London GM, Asmar RG, O'Rourke MF, et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/41\">",
"      Safar ME. Pulse pressure: a help in medical semiology for metabolic syndrome. Am J Hypertens 2007; 20:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/42\">",
"      Knudsen ST, Andersen NH, Poulsen SH, et al. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. Am J Hypertens 2008; 21:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/43\">",
"      Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/44\">",
"      Oparil S, Izzo JL Jr. Pulsology rediscovered: commentary on the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/45\">",
"      Wilkinson IB, McEniery CM, Cockcroft JR. Atenolol and cardiovascular risk: an issue close to the heart. Lancet 2006; 367:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26823/abstract/46\">",
"      Franklin SS. Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. J Hypertens Suppl 1999; 17:S29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3858 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26823=[""].join("\n");
var outline_f26_12_26823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pulse pressure and age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FACTORS RESULTING IN INCREASED PULSE PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Increases in systolic pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Decreases in diastolic pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INCREASED PULSE PRESSURE AND ADVERSE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53450682\">",
"      Pulse pressure and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53450556\">",
"      Pulse pressure and diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53450570\">",
"      Pulse pressure and progression of chronic kidney disease (CKD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PULSE PRESSURE AND ANTIHYPERTENSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONCLUSIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3858|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/50/5934\" title=\"figure 1\">",
"      Pulse pressure risk CHD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_12_26824="Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis";
var content_f26_12_26824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26824/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26824/contributors\">",
"     Marco Cicardi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26824/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26824/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/12/26824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired deficiency of C1 inhibitor (C1-INH), also called acquired angioedema (AAE), is a rare syndrome of recurrent episodes of angioedema, without urticaria, which is associated with B cell lymphoproliferative disorders in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Angioedema typically affects the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. The swelling is self-limited, although laryngeal involvement may cause fatal asphyxiation. Clinically, this disorder is very similar to hereditary angioedema (HAE), although AAE most commonly develops in patients over the age of 40 years, some of whom have associated lymphoproliferative disorders, whereas HAE usually presents in younger patients who are otherwise healthy.",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical manifestations, epidemiology, pathogenesis, and diagnosis of acquired C1 inhibitor deficiency. The management and prognosis of this disorder are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary angioedema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"     \"Hereditary angioedema: Treatment of acute attacks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AAE is rare; the precise incidence is not known.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the group of 776 patients referred to the author's specialty center in Milan for angioedema without urticaria between 1993 and 2003, only 14 had an acquired C1-INH deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/3\">",
"       3",
"      </a>",
"      ]. Twenty-one additional patients were identified among referrals during the next six years (2004 to 2009). At one point in time, we estimated that we had diagnosed 46 patients with AAE and 545 patients with HAE, for a ratio of approximately 1 patient with AAE for every 12 with HAE.",
"     </li>",
"     <li>",
"      A 2010 literature review identified 168 probable cases [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, AAE is likely underdiagnosed and we have identified several factors that may contribute to this. (See",
"    <a class=\"local\" href=\"#H3419803\">",
"     'Obstacles to diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired angioedema (AAE) is characterized by recurrent episodes of angioedema, without urticaria or pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/2\">",
"     2",
"    </a>",
"    ]. Attacks are commonly triggered by trauma and psychological stress. As in hereditary angioedema (HAE), swelling episodes in AAE can be characterized into three types: cutaneous, gastrointestinal, or upper airway. The similarities and differences between AAE and HAE are summarized here. A more detailed discussion of each type of attack is found in the topic review of hereditary angioedema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper airway edema, frequently involving the larynx, is the most severe and potentially lethal location for both disorders. Around 50 percent of patients with AAE experience upper airway edema, and anoxic brain injury or death from upper airway obstruction can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=see_link&amp;anchor=H29#H29\">",
"     \"Acquired C1 inhibitor deficiency: Management and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most consistent difference between AAE and HAE is the age of onset of the disorder. AAE presents in the fourth decade of life or later [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a series of 46 patients with AAE from the author&rsquo;s center, the earliest age of angioedema appearance was 39 years. In comparison, more than 90 percent of patients with HAE experience their first symptoms before the age of 20 years.",
"   </p>",
"   <p>",
"    There are other subtle differences between the clinical manifestations of AAE and HAE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal attacks appear to be less frequent in AAE &mdash; Angioedema of the gastrointestinal mucosa presenting as recurrent colicky abdominal pain, distention, vomiting",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea is reported by nearly 80 percent of patients with HAE, while less than 50 percent of our AAE patients and around 30 percent of those from other centers reported gastrointestinal attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/5,9\">",
"       5,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cutaneous angioedema in AAE seems to affect the face more than the limbs, while in patients with HAE, swelling of the extremities is more typical [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/5\">",
"       5",
"      </a>",
"      ]. However, both disorders can cause swellings in both locations.",
"     </li>",
"     <li>",
"      Patients may report antecedent changes in the skin (ie, similar in appearance to erythema marginatum) prior to cutaneous or gastrointestinal angioedema episodes, although it is not as prevalent as in patients with hereditary angioedema. Skin findings are described elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link&amp;anchor=H12#H12\">",
"       \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\", section on 'Characteristic features of angioedema attacks'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSOCIATED DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired angioedema (AAE) was first described in two patients with lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/1\">",
"     1",
"    </a>",
"    ]. Since this initial report in 1972, the majority of patients diagnosed with acquired angioedema have been found to have an underlying disorder. In particular, there is an association with B cell malignancies (most often non-Hodgkin's lymphoma) and lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Autoimmune disorders are also identified in patients with AAE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A total of 136 cases of acquired C1 inhibitor deficiency were identified in one extensive review of the literature [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/11,16\">",
"       11,16",
"      </a>",
"      ]. An underlying disease was identified in 85 percent of patients, including the following disorders:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lymphatic malignancies in 35 percent",
"     </li>",
"     <li>",
"      Monoclonal gammopathy of uncertain significance (MGUS) in 32 percent",
"     </li>",
"     <li>",
"      Autoimmune diseases in 8 percent",
"     </li>",
"     <li>",
"      Adenocarcinoma and other malignancies in 6 percent (NB: Other than lymphoma and adenocarcinoma, no other specific types of malignancies have been reported with regularity)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series, approximately 70 percent of patients with AAE had an identifiable B cell lymphoproliferative disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both studies, about one-half of identified lymphoproliferative disorders were malignant (most often non-Hodgkin's lymphoma), while the other half were benign (most often MGUS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AAE usually arises in the setting of an uncontrolled clonal proliferation of B lymphocytes. However, the mechanism by which clonal B cell disorders lead to depletion of C1-inhibitor (C1-INH) and angioedema remains incompletely understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of bradykinin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angioedema of AAE appears to be mediated largely by bradykinin, as in hereditary angioedema (HAE) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/17\">",
"     17",
"    </a>",
"    ]. Tissue insult or injury normally activates the contact system, leading to the generation of bradykinin and other proinflammatory mediators. Bradykinin, acting through bradykinin 2 receptors, increases endothelial permeability via mechanisms involving nitric oxide, cyclic GMP, and other effector molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Bradykinin production is normally regulated by C1-INH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antibodies to C1-INH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most (although not all) patients with AAE have identifiable autoantibodies against the C1-INH protein [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. In our patient group, we were able to detect these antibodies in 31 of 42 patients (74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/24\">",
"     24",
"    </a>",
"    ]. One theory proposes that pathologic B lymphocyte proliferation results in expansion of a clone that produces antibodies that bind to CI-INH (\"neutralizing antibodies\"), causing steric hindrance and a functional deficiency of the C1-inhibitor protein.",
"   </p>",
"   <p>",
"    Normally, C1-INH interacts with its target proteases and is cleaved in the process. The cleaved and inactive inhibitor irreversibly binds to the protease and renders it inactive. However, in the presence of anti-C1-INH antibodies, C1-INH is still cleaved, but it cannot bind the protease, and the protease continues to function, leading to uncontrolled generations of bradykinin and angioedema.",
"   </p>",
"   <p>",
"    If this theory were correct, then AAE would be predicted to result in essentially the same pattern of complement abnormalities as HAE. However, this is not the case, as most patients with AAE demonstrate profound depletion of components of the classical complement pathway, as evidenced by low C1q (the measurable component of the C1 complex, C1q-r-s), which is not seen in patients with HAE. In addition, not all AAE patients with low C1q values have detectable anti-C1-INH antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between autoantibodies to C1-INH and lymphoproliferative disorders in patients with AAE is not clear either. An early study identified these neutralizing antibodies in otherwise healthy AAE patients and hypothesized that AAE could arise from an autoimmune mechanism, without an associated lymphoproliferative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/20\">",
"     20",
"    </a>",
"    ]. Based on this, two types of AAE were proposed: one paraneoplastic and the other autoimmune [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/25\">",
"     25",
"    </a>",
"    ]. However, subsequent work revealed that patients with and without autoantibodies to C1-INH develop lymphatic malignancies over time and at similar rates, indicating that this distinction is not clinically or prognostically relevant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/8,26\">",
"     8,26",
"    </a>",
"    ]. Thus, the division of AAE into these two types has been abandoned [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Activation of the classical complement pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second theory proposes that the pathogenesis of AAE involves massive activation of the classical complement pathway by the neoplastic lymphoid tissue or by the abnormal antibodies and subsequent depletion of normally functioning C1-INH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/11,27-29\">",
"     11,27-29",
"    </a>",
"    ]. Evidence includes increased in vivo turnover of radiolabeled C1q and C1-INH with concomitant normal C1-INH production by monocytes of the same patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In this theory, anti-C1-INH autoantibodies are either an aggravating factor or purely an epiphenomenon.",
"   </p>",
"   <p>",
"    An interesting patient was reported who had HAE and then developed non-Hodgkin&rsquo;s lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/30\">",
"     30",
"    </a>",
"    ]. With the appearance of the lymphoma, the patient's angioedema markedly worsened, and depletion of classical pathway complement components was apparent that had not been present before. This patient did not have detectable anti C1-INH antibodies, and the case supports the role of lymphoma tissue as activator of the classical complement pathway and as the trigger of angioedema symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have two patients in our cohort in which we have detected neither an associated disorder nor autoantibodies to C1-INH and in whom the mechanism underlying AAE remains unknown. We can hypothesize that these individuals have antibodies to C1-INH that elude detection in plasma because of a low titer or because they are bound to cell membranes. It is also possible that an entirely different mechanism exists in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56805866\">",
"    <span class=\"h2\">",
"     Other implicated etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of case reports have implicated infections, especially Helicobacter pylori, in the development of AAE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Eradication of H pylori was followed by reversal of the clinical and biochemical symptoms abnormalities of AAE, suggesting the possibility that this infection could have a pathogenetic role in the development of AAE. The author has seen a patient with echinococcus and AAE who improved after treatment of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/24\">",
"     24",
"    </a>",
"    ]. However, infections are unlikely to be related to pathogenesis in most patients and we do not suggest an exhaustive search for infections unless there are suggestive clinical and laboratory findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419754\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acquired C1 inhibitor deficiency (AAE) is based upon a suggestive clinical history and appropriate complement abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419761\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired angioedema (AAE) should be considered in patients with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodes of angioedema affecting the cutaneous tissues and mucous membranes of the upper respiratory and gastrointestinal tracts",
"     </li>",
"     <li>",
"      Symptoms beginning in the fourth decade of life or later",
"     </li>",
"     <li>",
"      No family history of angioedema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with AAE generally demonstrate all three of the above characteristics. Absence of a family history of angioedema, in isolation, is NOT diagnostic of AAE because more than 25 percent of patients with HAE carry a de novo mutation in C1-INH gene and therefore have no affected ancestors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/34\">",
"     34",
"    </a>",
"    ]. On the other hand, the presence of a family member with angioedema essentially excludes the diagnosis of AAE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419768\">",
"    <span class=\"h2\">",
"     Complement studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An algorithm for the diagnosis of angioedema due to C1-INH deficiency (acquired or hereditary) was published by an international consensus group (",
"    <a class=\"graphic graphic_algorithm graphicRef64553 \" href=\"UTD.htm?1/50/1825\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/35\">",
"     35",
"    </a>",
"    ]. In patients with isolated angioedema who are suspected of having a disorder of C1 inhibitor, the following tests should be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      C4 level",
"     </li>",
"     <li>",
"      C1 inhibitor antigenic level",
"     </li>",
"     <li>",
"      C1q level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with AAE demonstrate the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low C4",
"     </li>",
"     <li>",
"      Low C1q (usually &lt;50 percent of normal)",
"     </li>",
"     <li>",
"      Low or normal C1 inhibitor antigenic (or quantitative protein) level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient demonstrates these laboratory abnormalities, then a test of C1 inhibitor function should be obtained. Low function is required for the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef83098 \" href=\"UTD.htm?21/58/22444\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    C1q levels are usually &lt;50 percent of normal in patients with AAE. However, about 30 percent of the patients in two large series had C1q levels that were decreased, but &gt;50 percent of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/7,16\">",
"     7,16",
"    </a>",
"    ]. Finally, there are rare cases in which C1q levels are normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419775\">",
"    <span class=\"h2\">",
"     Additional studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other diagnostic tests are only occasionally required. These include genotyping, detection of antibodies directed against C1-INH, and detection of cleaved C1-INH by SDS PAGE electrophoresis and immunoblotting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419782\">",
"    <span class=\"h3\">",
"     Genotyping",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases of AAE in which C1q is normal, the complement findings of AAE are identical to HAE. Genotyping for mutations in the C1-INH gene (SERPING1), which are only found in HAE, would be the only definitive way to differentiate these disorders. However, genetic testing is not widely available. If testing is not available, we recommend screening and monitoring patients who develop HAE over the age of 40 years for the underlying diseases associated with AAE. (See",
"    <a class=\"local\" href=\"#H3419824\">",
"     'Evaluation for underlying disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419789\">",
"    <span class=\"h3\">",
"     Detection of anti-C1-INH antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other biochemical finding that is characteristic of AAE is the presence of anti-C1-INH autoantibodies in plasma. By comparison, approximately 30 percent of patients with AAE have these antibodies, as well as 3 percent of normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/36\">",
"     36",
"    </a>",
"    ]. As with other autoantibodies, no clear cut separation between the background noise of natural autoantibody production in otherwise healthy individuals and significant pathologic levels in AAE patients has been established, and there is no diagnostic titer above which a patient can be determined to have AAE. No commercial assay for measuring these antibodies is available, although an ELISA system can be set up in specialized laboratories and yields reliable results for investigational purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/23,37\">",
"     23,37",
"    </a>",
"    ]. Therefore, the finding of high titers of anti-C1-INH antibodies in a patient's serum is supportive of the diagnosis of AAE but the absence of these antibodies does not exclude the disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419796\">",
"    <span class=\"h3\">",
"     Electrophoresis for inactive inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;An additional test that may help to refine the diagnosis of AAE is the detection of cleaved C1-INH by SDS PAGE electrophoresis and immunoblotting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/25\">",
"     25",
"    </a>",
"    ]. C1-INH normally interacts with its target protease and is cleaved by this interaction. Cleaved C1-INH then irreversibly binds to the protease, rendering it inactive. However, in the presence of anti-C1INH antibodies, C1-INH is cleaved, but cannot bind the protease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/38\">",
"     38",
"    </a>",
"    ]. The protease then continues to function while cleaved, but inactive C1-INH remains in the circulation. The cleaved, inactive form can be distinguished by electrophoresis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26824/abstract/38\">",
"     38",
"    </a>",
"    ]. In contrast, the routine quantitative assay for antigenic levels of C1-INH cannot distinguish between cleaved inactive and uncleaved active C1-INH, which explains why patients with AAE can have normal CI-INH antigenic levels and low function with standard complement tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419803\">",
"    <span class=\"h2\">",
"     Obstacles to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is our clinical impression that AAE frequently evades diagnosis for a period of years. We believe there are several obstacles to diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Even among specialists, awareness of the existence of an acquired form of C1-INH deficiency is not widespread, and uncertainties regarding the pathogenesis and laboratory features of the disorder further complicate diagnosis.",
"     </li>",
"     <li>",
"      Patients with AAE lack a family history, so cases are not detected through family screenings, as with HAE.",
"     </li>",
"     <li>",
"      The diagnosis of a coexisting lymphoproliferative malignancy can overshadow other medical issues, including recurrent angioedema, which may be attributed to a paraneoplastic phenomenon and not evaluated further.",
"     </li>",
"     <li>",
"      Because the disorder begins later in life, many patients are taking multiple medications and the episodes of angioedema are attributed to drug allergic reactions. Similarly, patients may have multiple comorbidities, and the evaluation of angioedema may not take precedence until a severe attack occurs.",
"     </li>",
"     <li>",
"      Complement abnormalities may fluctuate between normal and abnormal when the disorder first develops, becoming more consistently abnormal over the ensuing months. For this reason, mild abnormalities associated with a consistent clinical presentation should be followed over time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419810\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of acquired angioedema includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angioedema induced by ACE inhibitors",
"     </li>",
"     <li>",
"      Hereditary angioedema with normal C1 inhibitor or Type III HAE (formerly called estrogen-dependent hereditary angioedema)",
"     </li>",
"     <li>",
"      Isolated angioedema as a manifestation of an allergic reaction",
"     </li>",
"     <li>",
"      Idiopathic angioedema (ie, angioedema with no associated complement abnormalities)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In each of the above disorders, complement studies are normal.",
"   </p>",
"   <p>",
"    AAE can also be confused with hereditary angioedema (HAE) type 1 and type 2, which have similar clinical features and complement abnormalities. However, C1q is low in most patients with AAE and normal in those with HAE (",
"    <a class=\"graphic graphic_table graphicRef83098 \" href=\"UTD.htm?21/58/22444\">",
"     table 1",
"    </a>",
"    ). In addition, HAE usually presents in young people who are otherwise healthy, and about 75 percent of HAE patients have a family history of angioedema.",
"   </p>",
"   <p>",
"    The differential diagnosis of angioedema, in general, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=see_link&amp;anchor=H21#H21\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419817\">",
"    <span class=\"h2\">",
"     Low C1q levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low levels of C1q are not exclusive to acquired C1 inhibitor deficiency. Autoantibodies to C1q, causing depressed C1q levels, can be seen in hypocomplementemic urticarial vasculitis syndrome (HUVS) and SLE. Levels of C1q less than 30 percent of normal are typical of both conditions. However, HUVS usually includes urticaria, which is not observed with inherited or acquired C1-inhibitor deficiency. The diagnosis of HUVS and SLE are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"     \"Urticarial vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419824\">",
"    <span class=\"h1\">",
"     EVALUATION FOR UNDERLYING DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with acquired C1 inhibitor disorders should be evaluated for an underlying B cell lymphoproliferative disorder. This evaluation begins with a thorough review of systems and physical examination. Any abnormalities identified should be investigated further. Referral to a clinician trained in hematology can help with this evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the review of systems and physical examination is unrevealing, we usually obtain the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count (CBC), white blood cell differential, platelet count, and examination of the peripheral smear for the presence of atypical cells.",
"     </li>",
"     <li>",
"      Biochemical tests including blood urea nitrogen (BUN), creatinine, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH).",
"     </li>",
"     <li>",
"      Urinalysis.",
"     </li>",
"     <li>",
"      Serum protein electrophoresis and immunofixation.",
"     </li>",
"     <li>",
"      Serum free light chain assay (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H2212928#H2212928\">",
"       \"Recognition of monoclonal proteins\", section on 'Serum free light chains'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Screening for lymphadenopathy and masses with imaging studies of the chest and abdomen. We usually perform chest x-ray and abdominal ultrasound, although computed tomography (CT) scans are also an option.",
"     </li>",
"     <li>",
"      All age-appropriate cancer screening (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=see_link\">",
"       \"Screening for lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"       \"Screening for breast cancer\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3419831\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;If no associated condition is identified, then we monitor patients by repeating studies for B cell malignancies annually. Specifically, we obtain CBC with differential, serum protein electrophoresis and immunofixation, chest radiograph, and abdominal ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquired C1 inhibitor deficiency (also called acquired angioedema or AAE) is a rare disorder characterized by recurrent episodes of angioedema, without urticaria or pruritus. Swelling most often involves the subcutaneous tissues of the face and the submucosa of the upper airway and small bowel. AAE presents in the fourth decade of life or later. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 70 percent of patients with AAE are found to have an associated disorder. In one-half of cases, the disorder is malignant (most often non-Hodgkin's lymphoma) and the other half, the associated condition is benign (most often MGUS). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Associated disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angioedema in AAE is bradykinin-mediated, but the precise pathogenesis is undefined. Most patients have autoantibodies against the C1 inhibitor protein. These autoantibodies may impede the normal functioning of C1 inhibitor and cause a functional deficiency. Alternatively, the antibodies, or perhaps neoplastic tissue in some cases, may cause activation of the classical complement pathway, leading to depletion of normally functioning C1 inhibitor. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired C1 inhibitor deficiency (acquired angioedema, AAE) should be considered in a patient who presents with isolated angioedema (without urticaria) in the fourth decade of life or later, and has no family history of angioedema. (See",
"      <a class=\"local\" href=\"#H3419754\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial testing should consist of levels of C4, C1q, and C1 inhibitor (antigenic level). If C4 and C1q are low and C1 inhibitor antigenic level is low or normal, then C1 inhibitor function should be obtained. Low C1 inhibitor function confirms the diagnosis (",
"      <a class=\"graphic graphic_algorithm graphicRef64553 \" href=\"UTD.htm?1/50/1825\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83098 \" href=\"UTD.htm?21/58/22444\">",
"       table 1",
"      </a>",
"      ). Other studies are usually not needed. (See",
"      <a class=\"local\" href=\"#H3419768\">",
"       'Complement studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with acquired C1 inhibitor disorders should be evaluated for an underlying B cell lymphoproliferative disorder at the time of diagnosis. If no disorder is found, we recommend repeating an evaluation annually. (See",
"      <a class=\"local\" href=\"#H3419824\">",
"       'Evaluation for underlying disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/1\">",
"      Caldwell JR, Ruddy S, Schur PH, Austen KF. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol 1972; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/2\">",
"      Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/3\">",
"      Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/4\">",
"      Breitbart SI, Bielory L. Acquired angioedema: Autoantibody associations and C1q utility as a diagnostic tool. Allergy Asthma Proc 2010; 31:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/5\">",
"      Bouillet-Claveyrolas L, Ponard D, Drouet C, Massot C. Clinical and biological distinctions between type I and type II acquired angioedema. Am J Med 2003; 115:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/6\">",
"      Dobson G, Edgar D, Trinder J. Angioedema of the tongue due to acquired C1 esterase inhibitor deficiency. Anaesth Intensive Care 2003; 31:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/7\">",
"      Gelfand JA, Boss GR, Conley CL, et al. Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore) 1979; 58:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/8\">",
"      Fr&eacute;meaux-Bacchi V, Guinnepain MT, Cacoub P, et al. Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. Am J Med 2002; 113:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/9\">",
"      Eck SL, Morse JH, Janssen DA, et al. Angioedema presenting as chronic gastrointestinal symptoms. Am J Gastroenterol 1993; 88:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/10\">",
"      D'Incan M, Tridon A, Ponard D, et al. Acquired angioedema with C1 inhibitor deficiency: is the distinction between type I and type II still relevant? Dermatology 1999; 199:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/11\">",
"      Schreiber AD, Zweiman B, Atkins P, et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood 1976; 48:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/12\">",
"      Cicardi M, Zingale LC, Pappalardo E, et al. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003; 82:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/13\">",
"      Sheffer AL, Austen KF, Rosen FS, Fearon DT. Acquired deficiency of the inhibitor of the first component of complement: report of five additional cases with commentary on the syndrome. J Allergy Clin Immunol 1985; 75:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/14\">",
"      Castelli R, Deliliers DL, Zingale LC, et al. Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica 2007; 92:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/15\">",
"      Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev 2008; 8:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/16\">",
"      Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am 2006; 26:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/17\">",
"      Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/18\">",
"      Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004; 3:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/19\">",
"      Leeb-Lundberg LM, Marceau F, M&uuml;ller-Esterl W, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/20\">",
"      Jackson J, Sim RB, Whelan A, Feighery C. An IgG autoantibody which inactivates C1-inhibitor. Nature 1986; 323:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/21\">",
"      He S, Tsang S, North J, et al. Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency. J Immunol 1996; 156:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/22\">",
"      Mandle R, Baron C, Roux E, et al. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J Immunol 1994; 152:4680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/23\">",
"      Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987; 316:1360.",
"     </a>",
"    </li>",
"    <li>",
"     Cicardi M, unpublished data.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/25\">",
"      Alsenz J, Lambris JD, Bork K, Loos M. Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies. J Clin Invest 1989; 83:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/26\">",
"      Cicardi M, Beretta A, Colombo M, et al. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Clin Exp Immunol 1996; 106:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/27\">",
"      Hauptmann G, Lang JM, North ML, et al. Acquired c1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. A study of three cases. Blut 1976; 32:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/28\">",
"      Melamed J, Alper CA, Cicardi M, Rosen FS. The metabolism of C1 inhibitor and C1q in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1986; 77:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/29\">",
"      Jackson J, Sim RB, Whaley K, Feighery C. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema. J Clin Invest 1989; 83:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/30\">",
"      Guilarte M, Luengo O, Nogueiras C, et al. Acquired angioedema associated with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol 2008; 18:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/31\">",
"      Farkas H, Gyeney L, Majth&eacute;nyi P, et al. Angioedema due to acquired C1-esterase inhibitor deficiency in a patient with Helicobacter pylori infection. Z Gastroenterol 1999; 37:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/32\">",
"      Varvarovska J, Sykora J, Stozicky F, Chytra I. Acquired angioedema and Helicobacter pylori infection in a child. Eur J Pediatr 2003; 162:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/33\">",
"      Mukeba D, Chandrikakumari K, Giot JB, et al. Autoimmune angioneurotic edema in a patient with Helicobacter pylori infection. Helicobacter 2009; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/34\">",
"      Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/35\">",
"      Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/36\">",
"      Varga L, Sz&eacute;plaki G, Visy B, et al. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate na&iuml;ve patients. Mol Immunol 2007; 44:1454.",
"     </a>",
"    </li>",
"    <li>",
"     An assay for C1 inhibitor autoantibody is available through National Jewish Health Advanced Diagnostic Laboratories. Phone 800 555 6227. www.NJIlabs.org (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26824/abstract/38\">",
"      Malbran A, Hammer CH, Frank MM, Fries LF. Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J Allergy Clin Immunol 1988; 81:1199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8112 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26824=[""].join("\n");
var outline_f26_12_26824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSOCIATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of bradykinin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antibodies to C1-INH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Activation of the classical complement pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56805866\">",
"      Other implicated etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3419754\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3419761\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3419768\">",
"      Complement studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3419775\">",
"      Additional studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3419782\">",
"      - Genotyping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3419789\">",
"      - Detection of anti-C1-INH antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3419796\">",
"      - Electrophoresis for inactive inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3419803\">",
"      Obstacles to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3419810\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3419817\">",
"      Low C1q levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3419824\">",
"      EVALUATION FOR UNDERLYING DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3419831\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8112\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8112|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/50/1825\" title=\"algorithm 1\">",
"      C1-INH deficiency diagnostic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8112|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/58/22444\" title=\"table 1\">",
"      Comparison of complement studies in angioedema disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=related_link\">",
"      Hereditary angioedema: Prevention of attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=related_link\">",
"      Screening for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_12_26825="Management of refractory pemphigus vulgaris and pemphigus foliaceus";
var content_f26_12_26825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of refractory pemphigus vulgaris and pemphigus foliaceus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26825/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26825/contributors\">",
"     Michael Hertl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26825/contributors\">",
"     R&uuml;diger Eming, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26825/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26825/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26825/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/12/26825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13593182\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pemphigus vulgaris and pemphigus foliaceus are autoimmune blistering diseases that may result in significant morbidity and death. First-line treatment for pemphigus consists of systemic immunosuppression with systemic glucocorticoids with or without adjuvant immunosuppressive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42601?source=see_link\">",
"     \"Initial management of pemphigus vulgaris and pemphigus foliaceus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who do not respond to first-line therapies may benefit from additional interventions. Treatment regimens that include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , intravenous immunoglobulin (IVIG), immunoadsorption, or plasmapheresis may lead to clinical improvement in these patients.",
"   </p>",
"   <p>",
"    The treatment of pemphigus vulgaris and pemphigus foliaceus refractory to initial therapies will be reviewed here. The initial management of pemphigus vulgaris and pemphigus foliaceus, and the management of paraneoplastic pemphigus are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42601?source=see_link\">",
"     \"Initial management of pemphigus vulgaris and pemphigus foliaceus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=see_link&amp;anchor=H7465430#H7465430\">",
"     \"Paraneoplastic pemphigus\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255874776\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to the treatment of pemphigus vulgaris and pemphigus foliaceus consists of systemic glucocorticoid therapy, which is often given in conjunction with an adjuvant nonsteroidal immunosuppressant, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. The term refractory pemphigus is generally used to refer to pemphigus that fails to respond sufficiently to optimal administration of these agents. The initial management of pemphigus is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42601?source=see_link\">",
"     \"Initial management of pemphigus vulgaris and pemphigus foliaceus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various definitions for refractory pemphigus have been utilized in the medical literature. In 2008, a panel of experts proposed standardized definitions for the assessment of therapeutic responses in pemphigus for use in clinical studies, including definitions of treatment failure from certain therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/4\">",
"     4",
"    </a>",
"    ]. The consistent use of these guidelines in clinical studies may facilitate systematic interpretation of the literature in the future and may provide further clarification on therapeutic efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13593189\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pemphigus is a chronic disorder that usually requires treatment for a period of years. A retrospective study of 40 patients with pemphigus vulgaris who were seen in an academic medical center between 1983 and 1993 and followed for an average of 7.7 years found that long-lasting complete remission (ie, complete clinical remission off systemic therapy for at least six months) was achieved in 25 percent after two years, 50 percent after five years, and 75 percent after 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the majority of patients with pemphigus vulgaris or pemphigus foliaceus (around 60 to 80 percent) can achieve at least initial improvement with first-line therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], other patients fail to respond or experience frequent relapses while on these therapies. Our first steps for patients who fail initial therapy are to optimize the dose of the systemic glucocorticoid (up to a maximum of an equivalent of 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) and adjuvant agent, or to change the adjuvant therapy to a different first-line agent (eg, change from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or vice versa). If an adequate response still cannot be obtained, we proceed with the initiation of other therapies.",
"   </p>",
"   <p>",
"    The major therapeutic options for refractory disease include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , a drug that may be used as an alternative adjuvant immunosuppressant, and interventions that directly target the antibody-mediated pathogenesis of pemphigus, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , intravenous immunoglobulin (IVIG), immunoadsorption, and plasmapheresis. Concern for the unfavorable adverse effect profile of cyclophosphamide and the high cost of rituximab, IVIG, immunoadsorption, and plasmapheresis contribute to the preferred use of these agents for refractory pemphigus, rather than for new-onset disease.",
"   </p>",
"   <p>",
"    In addition to patients who fail to respond to first-line regimens, other patients with pemphigus may benefit from the therapies utilized for refractory disease. Patients with contraindications to initial therapies or who are unable to tolerate initial treatments may also benefit from treatments used for refractory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36962895\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7885644\">",
"    <span class=\"h2\">",
"     Treatment selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paucity of high-quality studies on the treatments for refractory pemphigus impedes both conclusions on the relative efficacies of interventions as well as the formation of definitive guidelines on the best approach to the treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, therapeutic choice remains heavily influenced by consideration of patient tolerability for specific treatments and treatment availability. In particular, treatment-specific contraindications should be considered.",
"   </p>",
"   <p>",
"    Examples of clinical scenarios that have influenced the choice of therapy for our patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preference to avoid",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in a patient of child-bearing potential due to the risk of cyclophosphamide-induced premature gonadal failure",
"     </li>",
"     <li>",
"      Preference to avoid extracorporeal therapies such as immunoadsorption and plasmapheresis in older patients with severe heart disease",
"     </li>",
"     <li>",
"      Preference for use of a rapid-acting therapy (eg, immunoadsorption) in patients with severe manifestations of the disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment availability is a major factor in treatment selection that is based on both the ability to obtain a treatment and access to appropriate equipment and expertise to administer it safely. For example, although the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for refractory pemphigus has decreased in clinical settings where patients have access to other less toxic treatment options, the relatively higher cost and more limited availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , IVIG, immunoadsorption, and plasmapheresis contributes to the continued use of cyclophosphamide in certain clinical settings. Whenever possible, the therapies utilized for refractory pemphigus should be administered by clinicians experienced in the use and adverse effects of these treatments. Referral to specialized treatment centers can be useful for additional access to treatments.",
"   </p>",
"   <p>",
"    We manage most patients with refractory pemphigus with the addition of one of the therapeutic options for refractory pemphigus to baseline immunosuppressive regimen that consists of systemic glucocorticoids with or without a first-line adjuvant medication. Although combination therapy with immunoadsorption and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has been utilized ourselves and other clinicians for patients with severe, refractory disease (extensive involvement or involvement of mucosal sites that may result in significant morbidity [conjunctiva, pharynx, larynx, or esophagus]), additional studies are necessary to confirm whether this approach is ideal. (See",
"    <a class=\"local\" href=\"#H36961953\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13593203\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment regimens that include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may be useful for inducing remission in pemphigus and reducing dependence on systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/6\">",
"     6",
"    </a>",
"    ]. The beneficial effect of cyclophosphamide in pemphigus is likely related to the drug&rsquo;s suppressive effect on B lymphocytes and the ensuing reduction in autoantibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/10\">",
"     10",
"    </a>",
"    ]. The adverse effect profile of cyclophosphamide contributes to restriction of its use primarily for refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H168239455\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168238886\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is usually prescribed as an adjuvant to systemic glucocorticoid therapy. Treatment regimens utilized for cyclophosphamide have varied. Several series have documented high rates of successful treatment of pemphigus with a pulsed regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and cyclophosphamide (monthly infusion of dexamethasone [100 mg for three days] and cyclophosphamide [500 mg for one day] plus daily 50 mg doses of oral cyclophosphamide in between pulsed therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. However, less consistently favorable results with this regimen have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A glucocorticoid-sparing effect of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    given in a different regimen was demonstrated in a one-year randomized trial (n = 120) that compared the efficacy of four different regimens for newly diagnosed pemphigus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/6\">",
"     6",
"    </a>",
"    ]. Although the rate of clinical response was similar among patients treated with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day followed by a taper) and cyclophosphamide (one 1000 mg intravenous dose per month for six months and every other month thereafter) and patients treated with prednisolone alone (73 and 77 percent, respectively), the cyclophosphamide group had a lower mean total dose of prednisolone (8276 mg versus 11,631 mg). Further, the glucocorticoid-sparing effects of cyclophosphamide were similar to the glucocorticoid-sparing effects of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil.",
"   </p>",
"   <p>",
"    The effects of treatment regimens with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    specifically on patients with refractory pemphigus have been evaluated in uncontrolled studies that have demonstrated favorable results in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective uncontrolled study, 23 patients with pemphigus (20 pemphigus vulgaris, 3 pemphigus foliaceus) who had disease refractory to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, who could not tolerate other therapies, or who had rapidly progressive extensive disease, were treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of ideal body weight per day) and prednisone (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of ideal body weight per day followed by a taper after two to three months) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/16\">",
"       16",
"      </a>",
"      ]. Of note, nine patients with severe disease also received plasma exchange during the first two weeks of treatment.",
"      <br/>",
"      <br/>",
"      Complete remission (defined as the absence of lesions for at least four weeks while on treatment with cyclophosphamide and less than 0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of prednisone) was achieved by 17 of 20 patients with pemphigus vulgaris (85 percent) and 2 of 3 patients with pemphigus foliaceus. Three patients with pemphigus vulgaris failed to respond to treatment and one patient with pemphigus foliaceus had a partial response. The median time to remission was 8.5 months for patients who did not receive plasma exchange, and 8 months for those who received the additional treatment. Six of 12 patients who achieved complete remissions and subsequently discontinued treatment with cyclophosphamide relapsed within a median time of six months.",
"     </li>",
"     <li>",
"      In a retrospective study, 21 patients with pemphigus refractory to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (18 pemphigus vulgaris, 2 pemphigus foliaceus, 1 paraneoplastic pemphigus) were treated with 4 to 22 pulses of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1 g per day for three consecutive days) together with 500 mg of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      on the second day of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/11\">",
"       11",
"      </a>",
"      ]. Between the monthly pulse treatments, patients were given oral cyclophosphamide (50 mg per day) and prednisolone. Continuation of adjuvant therapy with other immunosuppressives (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      methotrexate) was allowed.",
"      <br/>",
"      <br/>",
"      The study found a statistically significant reduction in skin and oral disease scores after treatment, and seven patients (33 percent) achieved an excellent response (defined as quiescent disease), and a lesser degree of response was observed in an additional 13 patients. The median number of pulses given to patients who achieved an excellent response was 12 (range 6 to 19). In addition, four patients with excellent responses achieved clinical remissions (defined as complete resolution of blisters and erosions for at least six months) that lasted for six months to six years. One of these patients was able to completely discontinue treatment while the other three remained on mycophenolate mofetil and low-dose prednisolone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A few case reports have documented the successful use of immunoablative high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for severe, refractory pemphigus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, treatment is not uniformly effective, and a disease flare within weeks after treatment has been reported in a patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168239455\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of this cytotoxic drug include myelosuppression, systemic infections, urine bladder toxicity, increased malignancies, and premature gonadal failure. Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    should be closely monitored for adverse effects of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H24#H24\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13593210\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the rationale that pemphigus is primarily an autoantibody-driven autoimmune disorder, therapies that deplete autoreactive B cell clones have been investigated for the treatment of pemphigus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    , a monoclonal antibody directed against the CD20 antigen on B lymphocytes, has demonstrated efficacy for pemphigus vulgaris and pemphigus foliaceus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The immunological effects of rituximab that contribute to its benefit in pemphigus may be complex; long-lasting B-cell depletion following rituximab treatment may be one significant factor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Additional findings during rituximab therapy that may be involved in the treatment effect include a preferential decline in autoantibodies compared with pathogen-specific antibodies (potentially due to a different effect of rituximab on autoreactive and pathogen-specific plasma cells) and a decline in autoreactive CD4+ T cells (a possible indirect effect of B cell depletion) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255875039\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initial reports of the positive impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    on paraneoplastic pemphigus in patients treated with rituximab for B-cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], multiple uncontrolled studies and case series have supported the efficacy of rituximab in patients with pemphigus vulgaris and pemphigus foliaceus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/20,29\">",
"     20,29",
"    </a>",
"    ]. In accordance with the emergence of rituximab therapy for pemphigus from patients with lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], dosing for rituximab in pemphigus initially reflected a regimen commonly used for lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/30\">",
"     30",
"    </a>",
"    ]. Since then, other dose regimens for rituximab have been evaluated in clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. However, the optimal dosing for rituximab for pemphigus vulgaris and pemphigus foliaceus remains to be determined. Rituximab is most commonly prescribed in combination with other systemic immunosuppressive therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36961907\">",
"    <span class=\"h4\">",
"     Lymphoma dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled studies and case series support a beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    given in a dose of 375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in various regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/20\">",
"     20",
"    </a>",
"    ]. The benefit of a single cycle of rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once weekly for four weeks) was illustrated in an open, multicenter study of 14 patients with pemphigus and 7 patients with pemphigus foliaceus. The patients had disease that was refractory to systemic glucocorticoids, had experienced multiple relapses during glucocorticoid tapering, or were unable to receive systemic glucocorticoids due to contraindications to glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/35\">",
"     35",
"    </a>",
"    ]. The treatment protocol consisted of rituximab and a systemic glucocorticoid that was tapered as tolerated. Five patients did not receive a systemic glucocorticoid due to contraindications for glucocorticoid therapy.",
"    <br/>",
"    <br/>",
"    Of the 21 patients, 18 (86 percent) achieved complete remission (defined as epithelialization of all lesions) within three months. The median time to complete remission for cutaneous pemphigus vulgaris, mucosal pemphigus vulgaris, and pemphigus foliaceus were 30, 90, and 60 days, respectively. Two additional patients achieved complete remission within six months and one year. Although nine of the patients who achieved complete remission relapsed during the course of the study within a mean of 19 months, seven of these patients were successfully managed with topical or systemic glucocorticoids, and the remaining two responded to a second course of rituximab.",
"   </p>",
"   <p>",
"    The number of treatments administered with this dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may influence patient outcomes. A retrospective analysis of 27 patients found that three or more infusions of rituximab (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once weekly) was associated with better patient outcomes than fewer treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36961921\">",
"    <span class=\"h4\">",
"     Rheumatologic dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    also appears to be effective for pemphigus when administered in a regimen similar to the regimen used for rheumatoid arthritis (two 1000 mg infusion separated by two weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Advantages of this dose over lymphoma dosing include the requirement for fewer infusion sessions and the often lower total dose of rituximab required for treatment.",
"   </p>",
"   <p>",
"    One of the largest prospective studies to evaluate the treatment of pemphigus with this protocol is a study of 42 patients with severe refractory pemphigus vulgaris (n = 37) or pemphigus foliaceus (n = 5) in which patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day followed by a taper to discontinuation) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/37\">",
"     37",
"    </a>",
"    ]. After six months, complete remission (defined as an absence of new or established lesions) occurred in 36 patients (86 percent), including 29 patients who had complete remissions for at least two months after treatment was stopped and seven patients who required minimal therapy (&le;10 mg per day of prednisone for at least two months).",
"   </p>",
"   <p>",
"    The median time to complete remission was 70 days (range 30 to 150 days).The seven patients who required minimal therapy were able to discontinue treatment within three additional months. An additional 500 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    led to complete remissions in the six patients who had partial remissions and to reinstitution of complete remission in 20 patients who relapsed. The median time to relapse was 16 months (range 6 to 41 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36961939\">",
"    <span class=\"h4\">",
"     Other protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    administered in lower doses than described above may be effective for pemphigus, though the duration of time to remission may be longer and the likelihood complete remission may be lower when compared to higher dose regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/34\">",
"     34",
"    </a>",
"    ]. The efficacy two 500 mg infusions of rituximab separated by two weeks was evaluated in a series of 15 adults with pemphigus vulgaris or pemphigus foliaceus that was refractory to conventional therapy or associated with major complications from glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/34\">",
"     34",
"    </a>",
"    ]. Of note, three patients received the second treatment at longer intervals due to health concerns or an inability to return for treatment. Concomitant treatment with other immunosuppressive agents was permitted.",
"   </p>",
"   <p>",
"    After a median followup of 94 weeks (range 32 to 152 weeks), 8 patients (53 percent) achieved a complete remission (defined as an absence of new or established lesions), four of whom achieved remission on minimal therapy (&le;10 mg per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    for at least two months) and four of whom had been able to discontinue all medication for at least two months. The median time to complete remission was 51 weeks. Partial remissions were achieved by seven patients (five on minimal therapy and two off all medication).",
"   </p>",
"   <p>",
"    No relapses occurred during the first year after treatment. However, six patients who had achieved a complete or partial remission (40 percent) relapsed during the second year of treatment (median time to relapse of 97 weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36961953\">",
"    <span class=\"h4\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has been combined with IVIG or immunoadsorption in attempts to take advantage of the fast onset of action of these therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Although rapid and long-lasting remissions have been reported in uncontrolled studies of patients with refractory pemphigus who were treated with combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/38-41\">",
"     38-41",
"    </a>",
"    ], the efficacy of rituximab given with and without these therapies has not been directly compared. Examples of studies that have evaluated combination therapy are provided:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled study of 11 patients with refractory pemphigus vulgaris, combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and IVIG was associated with rapid resolution of lesions in nine patients with clinical remissions lasting for an average of 31 months (range 22 to 37 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 23 patients with severe pemphigus treated with immunoadsorption,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , pulsed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, improvement in pemphigus was noted within a few weeks and 19 patients (83 percent) achieved long-term complete remissions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of 10 patients with refractory pemphigus vulgaris, 8 patients achieved complete remission within six months after the addition of immunoadsorption and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      to systemic glucocorticoids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glucocorticoid sparing agents [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an uncontrolled study of seven patients with severe or refractory pemphigus treated with immunoadsorption,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , and conventional immunosuppressants with or without IVIG, all patients had improvement in clinical manifestations within four weeks and three patients achieved long-term remissions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341812094\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although serious infections have been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for pemphigus, the effect of rituximab on risk for infections is unclear because of the concomitant use of other immunosuppressive drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/20\">",
"     20",
"    </a>",
"    ]. A 2009 review of 136 patients treated with rituximab for pemphigus found that severe infections were reported in about 10 percent of patients and fatal infectious events occurred in 3 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/20\">",
"     20",
"    </a>",
"    ]. Of note, progressive multifocal leukoencephalopathy has been reported in patients treated with rituximab for other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H16#H16\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Hypogammaglobulinemia and infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infusion reactions are a common side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy. Deep venous thrombosis, pulmonary embolism, long-term hypogammaglobulinemia, neutropenia have also been reported in patients treated with rituximab for pemphigus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H17#H17\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Other adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13593224\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin (IVIG)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) appears to be effective for refractory pemphigus. However, the mechanism through which IVIG improves pemphigus is not fully understood. Some authors have proposed that the infusion of IVIG may contribute to a reduction in circulating pemphigus autoantibodies by stimulating an increase in catabolism of immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341812371\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The highest quality evidence for a beneficial therapeutic effect of IVIG in pemphigus is provided by an 85-day multicenter, randomized trial in 61 adults with glucocorticoid-resistant pemphigus (defined as a failure to respond to equivalent of 20 mg per day or more of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients in the trial were treated with 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of IVIG per day for five days, 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of IVIG per day for five days, or a placebo infusion for five days. The primary endpoint in the trial was the duration of time that patients could be maintained on the treatment protocol before symptoms required additional treatment (ie, time to escape protocol).",
"   </p>",
"   <p>",
"    The trial found that the time to escape protocol was significantly longer for patients in the 400 mg IVIG group compared with the patients in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/45\">",
"     45",
"    </a>",
"    ], supporting a beneficial effect of the 400 mg dose of IVIG. The difference in the time to escape protocol for the 200 mg IVIG group and the placebo group was not statistically significant. Furthermore, a significant decrease in a pemphigus activity score was detected at all study observation points for patients in the 400 mg IVIG group and at all study observation points after day 15 in the 200 mg IVIG group. The pemphigus activity score did not decrease significantly at any time point in the placebo group.",
"   </p>",
"   <p>",
"    Several uncontrolled studies and case series provide additional support for the use of IVIG for refractory pemphigus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/44,46-50\">",
"     44,46-50",
"    </a>",
"    ]. In most of the series, patients received IVIG at a dose of 2",
"    <span class=\"nowrap\">",
"     g/kg/cycle",
"    </span>",
"    consisting of two to four consecutive treatment days, and IVIG cycles were repeated in four-week to six-week intervals. In some studies, clinical improvement following IVIG has been found to correlate with decreasing titers of desmoglein-specific IgG autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/44,50\">",
"     44,50",
"    </a>",
"    ]. Additionally, a glucocorticoid-sparing effect of adjuvant IVIG was suggested by a small retrospective study that found significant reductions in glucocorticoid requirements following treatment with adjuvant IVIG. [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341812364\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, IVIG therapy is well tolerated. Side effects are usually mild to moderate adverse events such as headache, back pain, increased blood pressure, and abdominal discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/45\">",
"     45",
"    </a>",
"    ]. Aseptic meningitis is a serious side effect of IVIG therapy that requires immediate termination of treatment. Anaphylaxis is a potential risk of IVIG treatment in patients with IgA deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36962160\">",
"    <span class=\"h2\">",
"     Immunoadsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoadsorption is a therapeutic option for pemphigus that functions through the removal of circulating autoantibodies. In contrast to plasmapheresis, which nonselectively removes plasma proteins from circulation, immunoadsorption removes circulating IgG with a very high specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/51\">",
"     51",
"    </a>",
"    ]. The high cost of immunoadsorption limits use of this therapy. In addition, immunoadsorption for pemphigus is not available in some countries, including the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36965124\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several apheresis systems for immunoadsorption have been successfully applied in pemphigus. The most effective columns include regenerative adsorber such as protein A or synthetic ligands (eg, PGAM146, Globaffin) that have a high affinity to the Fc-portion of human IgG [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/52-55\">",
"     52-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of immunoadsorption for removing pemphigus autoantibodies is influenced by the adsorber utilized and treatment protocol. In one study in which protein A adsorber was utilized, levels of antibodies against desmogleins 1 and 3 were reduced by an average of 76 percent one month after the start of immunoadsorption treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/52\">",
"     52",
"    </a>",
"    ]. Immunoadsorption is typically administered as an adjuvant to immunosuppressive therapies in short three to four day cycles that are repeated every three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/52-54,56\">",
"     52-54,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the clinical efficacy of immunoadsorption in pemphigus is primarily limited to small uncontrolled studies and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. The initial response to treatment can be rapid, occurring within a few weeks. Although long-term improvement after immunoadsorption has been reported in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/52,54\">",
"     52,54",
"    </a>",
"    ], additional studies are necessary to clarify the long-term effects of this treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36964247\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients appear to tolerate immunoadsorption well. Infrequently reported adverse effects that may be directly related to immunoadsorption therapy include hypotension, bradycardia, anaphylaxis, and sepsis from a central catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36962740\">",
"    <span class=\"h2\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with immunoadsorption, which specifically removes circulating IgG, plasmapheresis (also known as plasma exchange) nonselectively removes plasma proteins from circulation. Plasmapheresis is a more widely available therapy.",
"   </p>",
"   <p>",
"    Data are limited on the efficacy of plasmapheresis in pemphigus. Although small uncontrolled studies and case reports have associated improvement in pemphigus with plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/57-62\">",
"     57-62",
"    </a>",
"    ], a randomized trial of 40 patients in which treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    alone was compared to prednisolone plus plasmapheresis found no significant difference in efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36963996\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES FOR PEMPHIGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the major therapeutic options for the initial treatment of pemphigus vulgaris and pemphigus foliaceus and the management of refractory disease, multiple other interventions have been reported to be of benefit in small numbers of patients. Examples include topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/64\">",
"     64",
"    </a>",
"    ], topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/65\">",
"     65",
"    </a>",
"    ], biologic TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/66-70\">",
"     66-70",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , gold [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/71\">",
"     71",
"    </a>",
"    ], tetracyclines with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/72\">",
"     72",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , and mizoribine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26825/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13593245\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening disorders. First-line treatment for these diseases consists of a systemic glucocorticoid with or without an adjuvant immunosuppressant, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil. (See",
"      <a class=\"local\" href=\"#H13593189\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42601?source=see_link\">",
"       \"Initial management of pemphigus vulgaris and pemphigus foliaceus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who do not respond sufficiently to therapies used for the initial management of this disease may benefit from other interventions, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , intravenous immunoglobulin (IVIG), immunoadsorption, and plasmapheresis. (See",
"      <a class=\"local\" href=\"#H36962895\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to a lack of high-quality comparative trials, data are insufficient for definitive conclusions on the relative efficacies of therapies for refractory pemphigus. Factors such as patient tolerance for specific treatments and treatment availability influence treatment selection. (See",
"      <a class=\"local\" href=\"#H36962895\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/1\">",
"      Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; :CD006263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/2\">",
"      Mimouni D, Nousari CH, Cummins DL, et al. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003; 49:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/3\">",
"      Harman KE, Albert S, Black MM, British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/4\">",
"      Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/5\">",
"      Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/6\">",
"      Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/7\">",
"      Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/8\">",
"      Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/9\">",
"      Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011; 64:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/10\">",
"      Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 1987; 79:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/11\">",
"      Saha M, Powell AM, Bhogal B, et al. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus. Br J Dermatol 2010; 162:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/12\">",
"      Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/13\">",
"      Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990; 29:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/14\">",
"      Sacchidanand S, Hiremath NC, Natraj HV, et al. Dexamethasone-cyclophosphamide pulse therapy for autoimmune-vesiculobullous disorders at Victoria hospital, Bangalore. Dermatol Online J 2003; 9:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/15\">",
"      Rose E, Wever S, Zilliken D, et al. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges 2005; 3:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/16\">",
"      Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003; 49:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/17\">",
"      Nousari CH, Brodsky R, Anhalt GJ. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003; 49:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/18\">",
"      Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000; 43:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/19\">",
"      Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 2009; 129:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/20\">",
"      Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/21\">",
"      Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/22\">",
"      Arin MJ, Hunzelmann N. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update. Eur J Dermatol 2005; 15:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/23\">",
"      Pf&uuml;tze M, Eming R, Kneisel A, et al. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 2009; 218:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/24\">",
"      Nagel A, Podstawa E, Eickmann M, et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009; 129:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/25\">",
"      Eming R, Nagel A, Wolff-Franke S, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008; 128:2850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/26\">",
"      Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008; 128:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/27\">",
"      Borradori L, Lombardi T, Samson J, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001; 137:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/28\">",
"      Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001; 66:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/29\">",
"      Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges 2012; 10:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/30\">",
"      Zakka LR, Shetty SS, Ahmed AR. Rituximab in the Treatment of Pemphigus Vulgaris. Dermatol Ther (Heidelb) 2012; 2:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/31\">",
"      Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 2012; 148:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/32\">",
"      Leshem YA, Hodak E, David M, et al. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol 2013; 68:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/33\">",
"      Matsukura S, Knowles SR, Walsh S, Shear NH. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Arch Dermatol 2012; 148:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/34\">",
"      Horv&aacute;th B, Huizinga J, Pas HH, et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012; 166:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/35\">",
"      Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/36\">",
"      Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 2011; 165:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/37\">",
"      Cianchini G, Lupi F, Masini C, et al. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol 2012; 67:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/38\">",
"      Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/39\">",
"      Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2012; 166:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/40\">",
"      Behzad M, M&ouml;bs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 2012; 166:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/41\">",
"      Shimanovich I, Nitschke M, Rose C, et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/42\">",
"      Chakraborty S, Tarantolo SR, Treves J, et al. Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab. Case Rep Oncol 2011; 4:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/43\">",
"      Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/44\">",
"      Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol 2008; 58:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/45\">",
"      Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/46\">",
"      Herzog S, Schmidt E, Goebeler M, et al. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 2004; 84:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/47\">",
"      Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of High-dose Intravenous Immunoglobulin Therapy in 16 Patients with Refractory Autoimmune Blistering Skin Disease: High Efficacy and No Serious Adverse Events. Acta Derm Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/48\">",
"      Bystryn JC, Rudolph JL. IVI g TREATMENT OF PEMPHIGUS: how it works and how to use it. J Invest Dermatol 2005; 125:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/49\">",
"      Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002; 138:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/50\">",
"      Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol 2008; 144:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/51\">",
"      Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity 2006; 39:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/52\">",
"      Schmidt E, Klinker E, Opitz A, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/53\">",
"      L&uuml;ftl M, Stauber A, Mainka A, et al. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/54\">",
"      Eming R, Rech J, Barth S, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/55\">",
"      G&uuml;nther C, Laske J, Frind A, et al. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber. J Dtsch Dermatol Ges 2008; 6:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/56\">",
"      Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/57\">",
"      Ranugha PS, Kumari R, Kartha LB, et al. Therapeutic plasma exchange as a crisis option in severe pemphigus vulgaris. Indian J Dermatol Venereol Leprol 2012; 78:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/58\">",
"      Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1978; 98:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/59\">",
"      Roujeau JC, Andre C, Joneau Fabre M, et al. Plasma exchange in pemphigus. Uncontrolled study of ten patients. Arch Dermatol 1983; 119:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/60\">",
"      Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/61\">",
"      S&oslash;ndergaard K, Carstens J, J&oslash;rgensen J, Zachariae H. The steroid-sparing effect of long-term plasmapheresis in pemphigus. Acta Derm Venereol 1995; 75:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/62\">",
"      Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000; 43:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/63\">",
"      Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988; 124:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/64\">",
"      Iraji F, Asilian A, Siadat AH. Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol 2010; 9:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/65\">",
"      Cohen SN, Lim RP, Paul CJ, Abdullah A. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. Int J Dermatol 2006; 45:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/66\">",
"      Pardo J, Mercader P, Mahiques L, et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005; 153:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/67\">",
"      Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/68\">",
"      Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004; 74:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/69\">",
"      Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005; 141:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/70\">",
"      Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol 2009; 8:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/71\">",
"      Salomon D, Saurat JH. Oral gold therapy (Auranofin) in pemphigus vulgaris. Dermatologica 1986; 172:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/72\">",
"      Chen S, Lu X, Zhou G. Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline. Int J Dermatol 2003; 42:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26825/abstract/73\">",
"      Hashimoto T. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin Pharmacother 2008; 9:1519.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15304 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26825=[""].join("\n");
var outline_f26_12_26825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13593245\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13593182\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H255874776\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13593189\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36962895\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7885644\">",
"      Treatment selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13593203\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H168238886\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H168239455\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13593210\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H255875039\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36961907\">",
"      Lymphoma dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36961921\">",
"      Rheumatologic dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36961939\">",
"      Other protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36961953\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H341812094\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13593224\">",
"      Intravenous immunoglobulin (IVIG)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H341812371\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H341812364\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36962160\">",
"      Immunoadsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36965124\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36964247\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36962740\">",
"      Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36963996\">",
"      OTHER THERAPIES FOR PEMPHIGUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13593245\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42601?source=related_link\">",
"      Initial management of pemphigus vulgaris and pemphigus foliaceus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=related_link\">",
"      Paraneoplastic pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_12_26826="Treatment of dry eyes in Sjgren's syndrome";
var content_f26_12_26826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of dry eyes in Sj&ouml;gren's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26826/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26826/contributors\">",
"     Robert Fox, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26826/contributors\">",
"     Paul Creamer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26826/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/12/26826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/12/26826/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/12/26826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3377135\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren&rsquo;s syndrome (SS) is a chronic multisystem inflammatory disorder characterized by diminished lacrimal and salivary gland function. This results in the &ldquo;sicca complex,&rdquo; a combination of dry eyes (xerophthalmia) and dry mouth (xerostomia). A variety of other disease manifestations may also be present, including systemic signs and extraglandular features. The ocular condition of aqueous tear deficiency is termed &ldquo;keratoconjunctivitis sicca&rdquo; (a literal Latin translation of dry inflammation of cornea) but is also called keratitis sicca, xerophthalmia, or dry eye syndrome.",
"   </p>",
"   <p>",
"    SS occurs in a primary form not associated with other diseases and in a secondary form associated with other autoimmune rheumatic conditions, including rheumatoid arthritis and systemic lupus erythematosus.",
"   </p>",
"   <p>",
"    The treatment of dry eyes in patients with SS will be reviewed here. Other issues in SS are discussed separately, including the clinical manifestations; the diagnosis; the treatment of dry mouth and other non-ocular sicca symptoms; and the treatment of extraglandular manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=see_link\">",
"     \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dry eye syndromes unrelated to SS and an overview of dry eye disease, including the clinical manifestations, diagnosis, and management of dry eye unrelated to SS, are also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H720851756#H720851756\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Dry eye in older adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H31#H31\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Causes of ocular dryness and pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25784?source=see_link\">",
"     \"Dry eyes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3377142\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both local and systemic medical therapies are used in the treatment of SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/1\">",
"     1",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preventive therapies and attention to other conditions, medications, and environments that may cause or exacerbate dryness complaints",
"     </li>",
"     <li>",
"      Topical therapy of dry eyes, dry mouth, other dry mucosal surfaces, and dry skin, as well as the use of systemic cholinergic agents to stimulate secretions",
"     </li>",
"     <li>",
"      Systemic antiinflammatory and immunosuppressive therapies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to management of patients with sicca symptoms is generally the same for primary or secondary SS and depends upon the severity of symptoms and upon the responsiveness to therapy. Patients with mild SS may only require general preventive and topical treatment for sicca symptoms, in addition to monitoring of their condition and usual medical and dental preventive care.",
"   </p>",
"   <p>",
"    Most patients will benefit from multidisciplinary care. Treatment should be coordinated by a single clinician, usually a rheumatologist, in collaboration with the primary care physician and other clinicians. It is important that patients also be seen by an ophthalmologist with an interest in keratoconjunctivitis sicca (KCS). The dentist is also a critical member of the team that cares for these patients. The participation of other specialists may be required, depending upon the patient&rsquo;s particular clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=see_link\">",
"     \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comprehensive patient education should be provided regarding SS and its management, including use of available materials from professional societies and patient support groups. This is important because of the multisystem nature of the illness and because of the degree of self-care that is required. There should be particular attention to self-management strategies for tear conservation and for effective use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    , to treatment of dry mouth symptoms and oral hygiene, and to recognition of symptoms referable to other organ systems requiring specific medical attention.",
"   </p>",
"   <p>",
"    The aims of therapy for dry eyes are twofold: to provide relief of symptoms, including dryness, burning, and a sandy-gritty ocular irritation that gets worse as the day goes on, as well as itching, pain, ocular fatigue, diminished visual acuity, and pressure behind the eye; and to prevent injury of the eye, such as keratitis, erosions, neovascularization and ulceration of the cornea, and scarring of the ocular surface. Some experts prefer the use of the term &ldquo;dysfunctional tear syndrome&rdquo; rather than &ldquo;dry eye&rdquo; to reflect the inclusion of patients who have abnormalities in tear film composition but no reduction in tear volume.",
"   </p>",
"   <p>",
"    There are few large, well-designed, randomized trials that have evaluated the ability of most specific measures to prevent the complications of dry eyes in patients with SS. Our general approach is based upon the available trial data, upon small studies in patients with dry eyes both with and without SS, and upon our clinical experience. Treatment choices should be based upon the severity of disease and the response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach is generally consistent with recommendations of a consensus panel of international experts on the treatment of dry eye syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/2\">",
"     2",
"    </a>",
"    ]. The choice of therapies depends upon the severity of the disease. (See",
"    <a class=\"local\" href=\"#H3377156\">",
"     'Initial therapy and mild disease'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3377163\">",
"     'Moderate disease'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3377170\">",
"     'Severe disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3377156\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY AND MILD DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management in all patients should focus on tear conservation and on symptomatic relief. Such treatment may be sufficient in patients with mild or only episodic discomfort and in those with only mild signs of local disease, such as conjunctival injection (redness), or with no signs of local disease. Management includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient education regarding the disease and its complications, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Counseling regarding home, workplace, and other environmental factors that may worsen symptoms and self-management techniques for tear conservation (see",
"      <a class=\"local\" href=\"#H94900469\">",
"       'Tear conservation'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H94900496\">",
"       'Environmental management'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Instruction regarding signs and symptoms of blepharitis, which may be a complication of therapy or an independent condition and which may be misinterpreted as resistance to treatment (see",
"      <a class=\"local\" href=\"#H94901495\">",
"       'Potential complications'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of prescription and nonprescription systemic medications that may cause or exacerbate symptoms (see",
"      <a class=\"local\" href=\"#H94900523\">",
"       'Avoidance of medications causing dryness'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      as needed for relief of symptoms of ocular discomfort (see",
"      <a class=\"local\" href=\"#H94901467\">",
"       'Artificial tears'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94900469\">",
"    <span class=\"h2\">",
"     Tear conservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with dry eyes and SS should generally adopt measures for tear conservation. The use of medications that may worsen symptoms of dryness should be avoided, whenever possible. Physical barriers to conserve tear film can be helpful, but some patients prefer to limit the use of special eyewear for this purpose to severe disease. The use of these strategies is widely supported by experts in dry eye and is consistent with our clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, formal study of the effectiveness of these techniques is lacking, although they have no foreseeable significant risks. (See",
"    <a class=\"local\" href=\"#H94900496\">",
"     'Environmental management'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H94900523\">",
"     'Avoidance of medications causing dryness'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H94900550\">",
"     'Physical barriers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94900496\">",
"    <span class=\"h3\">",
"     Environmental management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to environments that exacerbate dry eyes should be minimized, and preventive strategies should be employed when such avoidance is impractical.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    should be used prophylactically to help prevent complications and to increase comfort,",
"    <strong>",
"     before",
"    </strong>",
"    entry into dry environments and then with increased frequency as compared with use in more humid environments. (See",
"    <a class=\"local\" href=\"#H94901467\">",
"     'Artificial tears'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following environments may be problematic:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dry or windy outdoor environments",
"     </li>",
"     <li>",
"      Dry indoor environments",
"     </li>",
"     <li>",
"      Areas with polluted air and other irritants, including the presence of smokers",
"     </li>",
"     <li>",
"      Hospital operating and recovery rooms [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/5\">",
"       5",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H94901188\">",
"       'Operating room and perioperative management'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computer use is associated with a decreased blink rate, and extended computer use can be especially problematic and may worsen dry eye [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Frequent, short breaks and additional longer breaks may be beneficial; other proposed therapies include efforts to increase the blink rate and the increased use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    . However, the degree of benefit of these interventions for dry eye related to computer use is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H94901467\">",
"     'Artificial tears'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of humidifiers is helpful in bedrooms and other rooms in which the patient spends a lot of time. The occasional use of a moist washcloth over the eyes can also provide symptomatic relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94901188\">",
"    <span class=\"h4\">",
"     Operating room and perioperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;An",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/14/34017?source=see_link\">",
"     ocular lubricant",
"    </a>",
"    should be used as a preventive measure prior to surgery. In addition, patients should be allowed to bring their topical medications for Sj&ouml;gren's syndrome from home if they are unavailable in the hospital; these medications should be available as needed. The level of humidity in operating rooms and in postoperative units may be very low, which increases the risk of dry eye complications, including corneal abrasions. Dryness is also worsened when non-humidified oxygen is administered by facemask. (See",
"    <a class=\"local\" href=\"#H14287258\">",
"     'Lubricant ointments'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94900523\">",
"    <span class=\"h3\">",
"     Avoidance of medications causing dryness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications used for treatment of other conditions may worsen symptoms of dryness, and alternatives should be sought whenever possible (",
"    <a class=\"graphic graphic_table graphicRef77821 \" href=\"UTD.htm?37/39/38524\">",
"     table 1",
"    </a>",
"    ). The degree to which such medications are relatively contraindicated depends upon the severity of disease for which the drug is being administered and upon the amount to which the drug worsens dryness in the dose used in a given patient. The use of multiple drugs that, individually, may have modest drying effects can also be problematic. Commonly used medications that may exacerbate dryness include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tricyclics (antidepressants also used for neuropathic pain)",
"     </li>",
"     <li>",
"      Antihistamines",
"     </li>",
"     <li>",
"      Diuretics",
"     </li>",
"     <li>",
"      Beta blockers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dryness of the eyes is often caused by the use of drugs with anticholinergic side effects, such as the tricyclic drugs and many others. The range of medications and the adverse effects of drugs with anticholinergic activity are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=see_link&amp;anchor=H6#H6\">",
"     \"Drug prescribing for older adults\", section on 'Anticholinergic activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ocular medication drops (such as antibiotics and medications for glaucoma) that contain preservatives may also be bothersome for patients with SS who require drops frequently. Thus, patients who require these medications may need to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    without preservatives to limit exposure to these additives. (See",
"    <a class=\"local\" href=\"#H94901481\">",
"     'Choice of replacement fluid'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94900550\">",
"    <span class=\"h3\">",
"     Physical barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moisture conserving eyewear can be employed to conserve tear film. These may most helpful in particular situations, such as when traveling into dry windy environments such as airplanes or long air-conditioned car rides, during which humidity is low, and while exercising, especially jogging or biking, during which increased dirt and decreased blink rate are encountered.",
"   </p>",
"   <p>",
"    Examples of moisture conserving eyewear include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Side shields, which can be fitted to glasses, reducing the evaporation rate of normal or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"     </li>",
"     <li>",
"      Wrap-around sunglasses, which are more socially acceptable to many patients than are side-shields or goggles",
"     </li>",
"     <li>",
"      Ski or swim goggles, which also reduce evaporation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the use of such physical barriers is often socially unacceptable, except to more severely affected patients when other measures are insufficient and to those with frequent or persistent exposure to adverse environments.",
"   </p>",
"   <p>",
"    Certain types of contact lenses may benefit selected patients with severe dry eye but are generally not used in patients with mild disease. (See",
"    <a class=\"local\" href=\"#H93302119\">",
"     'Contact lens use'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94901467\">",
"    <span class=\"h2\">",
"     Artificial tears",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the regular use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    in most patients with SS, including patients with all levels of disease severity. Patients may select these from the many available tear preparations, which differ in their composition, preservatives, osmolality, and viscosity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/3\">",
"     3",
"    </a>",
"    ] and which are typically available without prescription. Patients should try several different agents to identify the one that provides the most comfort, regardless of the theoretical advantage of the composition of one agent over another. (See",
"    <a class=\"local\" href=\"#H24634482\">",
"     'Artificial tear composition'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H94901481\">",
"     'Choice of replacement fluid'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The frequency of use should be guided by the need for symptomatic relief, such as reduced symptoms of irritation and improved visual acuity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    may be used indefinitely; however, tears containing preservatives should generally not be used more than four times daily. Patients using other topical ocular medications (eg, for glaucoma) should note whether these contain preservatives and should include the number of times such drops are employed in the assessment of whether preservative-free preparations are needed. (See",
"    <a class=\"local\" href=\"#H94901481\">",
"     'Choice of replacement fluid'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H94901495\">",
"     'Potential complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    in patients with SS is supported by several randomized trials that included patients with SS and moderate to severe dry eye [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. These trials showed symptomatic relief and improvements in damage to the corneal epithelium compared with baseline measurements. One compared hyaluronate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    eyedrops, showing that both improved symptoms and corneal surface findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/12\">",
"     12",
"    </a>",
"    ]. A different trial demonstrated greater benefit from hyaluronate compared with saline eye drops [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/13\">",
"     13",
"    </a>",
"    ], and another trial showed greater improvement with hypotonic compared with isotonic hyaluronate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies and small trials that have not included patients with SS have also shown benefits for the treatment of dry eyes. These included evaluation of various preparations other than hyaluronate that are a component of multiple, widely available products, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    . These benefits include symptomatic improvement, enhanced visual acuity, and improvement in ocular surface staining [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    are limited by their small size and by the use of only a few selected agents (including hyaluronate, which is generally not available for routine clinical use). Additionally, it is unclear which of the many available preparations provides the greatest improvement and which ingredients or formulations are most effective in improving subjective and objective outcomes that are clinically important [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/3,18\">",
"     3,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24634482\">",
"    <span class=\"h3\">",
"     Artificial tear composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    and lubricants are generally available without a prescription and may be in the form of liquid eyedrops, gels, or ointments. Gels and ointments often affect vision during use and are usually not required in patients with mild disease. However, they may be particularly useful when applied in the evening before sleep. (See",
"    <a class=\"local\" href=\"#H14287258\">",
"     'Lubricant ointments'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Typically, the major components of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A form of cellulose (eg, hypromellose or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"       carboxymethylcellulose",
"      </a>",
"      ), which is a major component of many dry eye tear products, which is beneficial for replacement of the aqueous layer, and which helps maintain viscosity",
"     </li>",
"     <li>",
"      Spreading agents (eg, polyvinyl alcohol, polyethylene glycol,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      ), which are contained in many drops and which help the aqueous layer to spread over the hydrophobic corneal and conjunctival epithelium and to prevent evaporation",
"     </li>",
"     <li>",
"      Mucolytic agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      ), which are useful in more severely affected patients when there is an overproduction of mucus that accumulates as filaments in the eye. However, an objectionable smell may limit use of these agents.",
"     </li>",
"     <li>",
"      Preservatives (eg, benzalkonium, thimerosal,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      , polysorbate 80), which prevent bacterial contamination and which prolong shelf life. However, these may lead to local irritation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94901481\">",
"    <span class=\"h3\">",
"     Choice of replacement fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can initially use drops containing hypromellose (0.3 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    (0.3 percent), as needed and up to every two to four hours (eg, Tears Naturale II, Liquifilm Tears, Liquifilm Forte, Tears Plus, IsoptoTears, and Viscotears). These drops also generally include a spreading agent and a preservative. The frequency of use varies with the degree of dryness, with the specific product used, and with the ambient humidity and other environmental factors. These tears differ in viscosity, also affecting how long they last following an application. Higher viscosity drops require less frequent application, but they may cause visual blurring and can increase the risk of blockage of the meibomian glands, with resultant blepharitis.",
"   </p>",
"   <p>",
"    Preservative-free preparations (eg, Tears Naturale Free, Bion Tears, HypoTears PF, Refresh, Moisture Eyes Free, and TheraTears Free) are preferred in patients who develop irritation from frequent use of tears containing preservatives. The irritation related to preservatives can be associated with ocular surface changes involving the cornea and conjunctiva, with abnormal tear film, and with inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/19\">",
"     19",
"    </a>",
"    ]. Such irritation may occur with use every two to four hours in some patients; thus, patients should generally avoid using drops containing preservatives more than four times daily. Preservative-free tears are typically supplied in single use dispensers. Potential disadvantages of these fluids are high cost and, for patients with arthritis, difficulty with opening the single use containers. These products may be available for purchase in bulk at lower cost through the internet.",
"   </p>",
"   <p>",
"    The benefits of switching from preserved to preservative-free formulations have not been formally evaluated in patients with SS but have been shown in both retrospective and prospective studies of patients being treated for glaucoma, in whom significant reductions in irritative symptoms and in signs of palpebral, conjunctival, and corneal injury were seen with reduced usage of preservative-containing drops, particularly after switching entirely to preservative-free drops [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. In one prospective study involving 158 patients, the number of patients with symptoms during treatment was reduced in half after switching to preservative-free medication, and the number of patients with abnormal signs was reduced by 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/22\">",
"     22",
"    </a>",
"    ]. As examples, symptoms of irritation, burning, and stinging and findings of corneal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    staining were both significantly reduced after 6 and 12 weeks with preservative-free drops (from 56 to 31 to 28 percent and from 82 to 53 to 41 percent, respectively).",
"   </p>",
"   <p>",
"    There are additional differences in individual preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/3,23\">",
"     3,23",
"    </a>",
"    ]. An example of a tear that has a decreased osmolality to compensate for higher salt concentrations in the dry eye is Hypotears. Systane drops include a lipid stabilizing agent. The addition of a mucolytic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    , which breaks up mucus strands and filaments, should be tried in patients who complain of sticky eyes in the morning or who have mucus filaments on examination. The patient should be warned of its unpleasant smell (like rotten eggs) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    containing sodium hyaluronate have been studied in patients with SS but are generally not used in the routine clinical care of SS because of cost, restricted availability, and difficulty with maintenance of sterility due to the way they are packaged for use in ophthalmologic surgery. (See",
"    <a class=\"local\" href=\"#H94901467\">",
"     'Artificial tears'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Slow release artificial tear inserts, which contain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29714?source=see_link\">",
"     hydroxypropyl cellulose",
"    </a>",
"    but no preservative, avoid the need for frequent instillation of drops. However, artificial tear inserts are no longer widely available and are difficult for many patients with arthritis to insert without incurring corneal abrasion from the application procedure. The patient must have enough tears to dissolve the pellet and enough dexterity to place the insert into the eye without damage to the corneal surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94901495\">",
"    <span class=\"h3\">",
"     Potential complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several problems that can be associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    , including irritation due to components of the drops themselves and blepharitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Itching or increased irritation of the eye may occur in some patients with use of drops that contain preservatives, stabilizers, or solubilizers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/19\">",
"       19",
"      </a>",
"      ]. A preservative that is acceptable to most patients without severe dry eyes may reach a higher concentration in the patient with dry eyes and may be more likely to cause problems. Although these additives extend the lifetime of products, they may produce local irritation and persistent symptoms despite the use of drops, especially if used every two to four hours. If this occurs, an alternative preparation can be tried, which is preservative-free or which uses a different preservative. The preservatives used in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      that are most responsible for irritation in dry eye patients (eg, benzalkonium chloride) have generally been replaced by less irritating compounds but may still be used in other types of eye drops.",
"     </li>",
"     <li>",
"      Blepharitis is caused by inflammation and infection (commonly staphylococcal) of the lid margins, including the meibomian glands of the eyelid; it can be worsened by the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      , especially those with high viscosity or those containing preservatives. Symptoms resemble those of SS, but, unlike SS, blepharitis is often associated with redness of the lower lids, with increased tearing, and with relatively normal Rose Bengal staining. It is important to consider blepharitis in the differential diagnosis of increased symptoms of ocular irritation. The evaluation and treatment of blepharitis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"       \"Blepharitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3377163\">",
"    <span class=\"h1\">",
"     MODERATE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with moderate episodic or chronic symptoms (even in the absence of environmental stress), additional measures and some changes in topical therapies are usually required while continuing initial preventive measures. (See",
"    <a class=\"local\" href=\"#H3377156\">",
"     'Initial therapy and mild disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Signs of disease in these patients are not always present. When present, they may include variable corneal staining, mild debris, or an abnormal Schirmer test, which is a test done to measure tear production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Tests for KCS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of such patients includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More frequent (every two to four hours) use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      , which often requires use of preservative-free preparations. We suggest use of a lubricating ointment at night for these patients, and a daytime gel formulation may be tried if relief is inadequate with artificial tears and an ointment at night. (See",
"      <a class=\"local\" href=\"#H94901481\">",
"       'Choice of replacement fluid'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14287258\">",
"       'Lubricant ointments'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Use of topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      topical glucocorticoids. The latter should be prescribed in collaboration with an ophthalmologist. Topical cyclosporin may take up to three months for effect, and topical glucocorticoids should only be used for short periods. (See",
"      <a class=\"local\" href=\"#H14287856\">",
"       'Topical cyclosporine'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1749513\">",
"       'Topical glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Use of punctal plugs for patients with moderate to severe disease who do not respond adequately to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      , topical lubricants, and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H1749892\">",
"       'Punctal occlusion'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We generally do not prescribe an orally administered secretagogue such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    for dry eyes alone, but patients with dry mouth who use these medications sometimes experience symptomatic relief and decreased ocular dryness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14287258\">",
"    <span class=\"h2\">",
"     Lubricant ointments",
"    </span>",
"    &nbsp;&mdash;&nbsp;At night, a longer-acting lubricant ointment (eg, Refresh PM, Lacrilube, Duratears, or Viscotears) is useful for patients with moderate to severe disease because it reduces the rate of tear evaporation; it may also cause blurring, which limits daytime use. Only a small amount (such as",
"    <span class=\"nowrap\">",
"     1/8",
"    </span>",
"    inch [2 to 3 mm]) should be used, since larger amounts are likely to lead to blockage of the meibomian glands and to increase risk of blepharitis. Patients using lubricants at night should perform lid-scrubs (using warm water and diluted baby shampoo [about 1 part in 300]) in the morning to prevent blepharitis. (See",
"    <a class=\"local\" href=\"#H94901495\">",
"     'Potential complications'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link&amp;anchor=H24#H24\">",
"     \"Blepharitis\", section on 'Lid washing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14287856\">",
"    <span class=\"h2\">",
"     Topical cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the use of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in patients without sufficient relief of symptoms from use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    and lubricants. Topical cyclosporine (0.05 percent ophthalmic emulsion) is administered as one drop (0.4 mL) twice daily and can be used together with artificial tears. Use is contraindicated in patients with active ocular infections. Plasma cyclosporine levels are generally undetectable with the use of the 0.05 percent ophthalmic emulsion twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/23,28\">",
"     23,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally try",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    drops prior to punctal occlusion because of the ease of use of the ophthalmic preparation and because of the minimal risk of adverse effects. However, there is a lack of trial evidence to determine the optimal sequence of therapies. Some ophthalmologists favor initial use of cyclosporine based upon the presumed benefit of decreasing the local level of inflammatory mediators while avoiding risk of high local concentrations of such mediators and metalloproteinases that may result from occlusion without adequate antiinflammatory therapy. Studies on topical cyclosporine did not show benefit in the subgroup of patients with punctal occlusion, but the combination of both cyclosporine and punctal plugging may be of greater benefit than either treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1749892\">",
"     'Punctal occlusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefits of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for patients with SS were shown in a series of randomized trials, which compared it with placebo and with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    , and in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/4,23,30\">",
"     4,23,30",
"    </a>",
"    ]. Clinical benefits in both subjective and objective measures of dry eye and in changes in the corneal surface occur in about 60 to 75 percent of patients with twice-daily dosing, and treated patients show a decrease in infiltrating T cells in conjunctival biopsies and other improvements in histology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/23,28,31-33\">",
"     23,28,31-33",
"    </a>",
"    ]. Responses take up to two to three months in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of evidence supporting the effectiveness and limited adverse effects of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 877 patients randomly assigned to receive twice-daily instillation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (0.05 percent or 0.1 percent) or vehicle alone, there was statistically significant improvement in objective measures (corneal staining and Schirmer testing) and in subjective measures (blurred vision, need for concomitant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      , and clinicians&rsquo; global evaluation of response to treatment) at time points between three and six months [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/28\">",
"       28",
"      </a>",
"      ]. As examples, the mean improvements in blurred vision and in artificial tear use after six months were statistically significantly greater for the patients using cyclosporine 0.05 percent compared with those using the vehicle alone (reductions of approximately 0.5 versus 0.1 to 0.2 on a 4 point scale, and reductions of nearly one-half versus one-tenth to one-fifth of a",
"      <span class=\"nowrap\">",
"       drop/day,",
"      </span>",
"      respectively). The clinician&rsquo;s subjective assessment of global response was improved in all groups at six months (slight response or better in 63 to 69 percent, and moderate response or better in 32 to 39 percent). There was no additional benefit of a higher dose.",
"      <br/>",
"      <br/>",
"      The most common adverse effect was a mild to moderate, usually transient, burning sensation or stinging in the eyes after administration (18 percent of patients receiving cyclosporine [0.05 percent solution] versus 8 percent of controls); only 2 percent of patients in the cyclosporine or control groups discontinued treatment because of burning or stinging. Less frequent side effects were red eye, epiphora (excessive watering of the eyes), foreign body sensation, itching, and blurred vision.",
"     </li>",
"     <li>",
"      Sustained benefit with continued use was shown in a study of 412 patients with moderate to severe dry eye disease in a one- to three-year extension of 6- to 12-month randomized trials in which patients had received 0.05 or 0.1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/34\">",
"       34",
"      </a>",
"      ]. The response to cyclosporine 0.1 percent ophthalmic emulsion was examined during the extension (mean duration of treatment of 19.8 months). Most survey respondents reported that their symptoms had begun to resolve in the first three months of cyclosporine treatment. During the extension, further improvements in objective and subjective measures of dry eye disease were modest, presumably because of the prior treatment. No serious treatment-related adverse events occurred.",
"     </li>",
"     <li>",
"      The superiority of topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      was shown in a trial involving a total of 150 patients, in which patients were randomly assigned to use preservative-free artificial tears (containing 0.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"       carboxymethylcellulose",
"      </a>",
"      sodium) four times daily together with either cyclosporine (0.05 percent) ophthalmic solution twice daily or vitamin A (retinyl palmitate, 0.05 percent) ophthalmic solution four times daily or to receive the artificial tears alone [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients who received topical cyclosporine had statistically significant improvement from baseline in blurred vision (from 1.21 &plusmn; 0.25 to 0.95 &plusmn; 0.19 [on a 0 to 4 scale] at month three); in tear film breakup time (from 3.4 &plusmn; 1.3 to 5.9 &plusmn; 2 seconds at month two); and in Schirmer testing (from 3.9 &plusmn; 1.2 to 7.3 &plusmn; 1.8 mm at month three). The effects of cyclosporine and vitamin A were comparable, while the artificial tears alone did not result in statistically significant improvement compared with baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with &ldquo;burning&rdquo; symptoms as a complication of starting topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , topical glucocorticoids (prescribed by an ophthalmologist) may be used to alleviate symptoms during the initial phase of cyclosporine treatment; the glucocorticoid drops can generally be tapered and discontinued over several weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1749513\">",
"     'Topical glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients who are refractory after three to four months to twice-daily treatment with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , the frequency of administration may be increased to three or four times per day. In one case series, six of nine patients with Sj&ouml;gren&rsquo;s syndrome, without an adequate response after four months of twice-daily therapy, experienced significant improvement in objective measures of dry eye after two months of treatment with three or four times daily dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients will usually know if the medication (together with the topical glucocorticoid drops) will be tolerated within two weeks. (See",
"    <a class=\"local\" href=\"#H1749513\">",
"     'Topical glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The indications for tapering or discontinuing the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    drops have not been clearly defined. We generally attempt to discontinue cyclosporin drops after symptoms have improved, because of the expense of the medication, and resume treatment for recurrent symptoms.",
"   </p>",
"   <p>",
"    In addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , other calcineurin inhibitors, including topical preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    , are under investigation and have exhibited benefit for keratoconjunctivitis sicca changes in animal trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749513\">",
"    <span class=\"h2\">",
"     Topical glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with moderate to severe disease and with signs of ocular inflammation, who have not responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    , lubricants, and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , topical glucocorticoids may be used in collaboration with an ophthalmologist for several weeks as pulse therapy. As topical glucocorticoids have potential risks, they should be administered under the direction and continued supervision of an ophthalmologist. Treatment is usually of limited duration because of concern regarding adverse effects such as glaucoma and cataract formation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of therapeutic options include 0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39684?source=see_link\">",
"     loteprednol",
"    </a>",
"    suspension, one drop applied topically (in the conjunctival sac) three to four times daily for two weeks, followed by a gradual taper over several weeks; in more severely affected patients or in those at lower risk for adverse effects, options include 0.1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41748?source=see_link\">",
"     fluorometholone",
"    </a>",
"    suspension, one drop applied topically two to four times daily, for a similar duration of therapy. Topical glucocorticoids may also be helpful as temporary adjunctive therapy early in the course of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for treatment of the side effects of burning or stinging that may occur with the latter agent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/36,38\">",
"     36,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14287856\">",
"     'Topical cyclosporine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of topical glucocorticoids is based upon relatively limited data, including several small randomized trials of varying duration, a small number of uncontrolled case series, and clinical experience. The randomized trials used several different agents and included patients with both Sj&ouml;gren&rsquo;s syndrome and other inflammatory eye disorders. The degree of benefit varies. The range of evidence is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two small randomized trials, in which benefit for moderate to severe dry eye patients was suggested by improvement within two weeks both in symptoms and in objective findings in patients given topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39684?source=see_link\">",
"       loteprednol",
"      </a>",
"      etabonate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41748?source=see_link\">",
"       fluorometholone",
"      </a>",
"      drops [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/38,41\">",
"       38,41",
"      </a>",
"      ]. In one trial, loteprednol reduced symptoms, but both loteprednol and vehicle use resulted in a similar degree of improvement in the worst symptoms compared with baseline values (26 to 28 mm on a 100 mm visual analogue scale) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/38\">",
"       38",
"      </a>",
"      ]. Topical fluorometholone plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      significantly reduced symptom severity compared with baseline and with artificial tears alone after both 15 days and 30 days of treatment (approximately 50 percent reduction compared with baseline or placebo) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/41\">",
"       41",
"      </a>",
"      ]. Adverse events did not differ between treated and control patients in each of these studies.",
"     </li>",
"     <li>",
"      Two case series in which substantial relief of symptoms and improvement in objective measures were also seen within two weeks from use of nonpreserved",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      drops, with moderate or complete relief of symptoms of irritation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/36,42\">",
"       36,42",
"      </a>",
"      ]. In one study, adverse effects were noted in 3 of the 13 patients who had continued lower-dose treatment beyond two weeks after symptoms worsened with efforts at weaning; these included increased intraocular pressure (n = 1) and worsening or development of cataracts (n = 2) after three and six months of therapy, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infectious complications, including fungal superinfections, should be considered in the patient on topical glucocorticoids with worsening symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749892\">",
"    <span class=\"h2\">",
"     Punctal occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest punctal occlusion using temporary punctal plugs or subsequent permanent punctal occlusion in patients with moderate to severe ocular dryness and with abnormal ocular findings, in whom frequent installation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    , lubricants, and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are inadequate or impractical. There is disagreement among experts regarding the type of punctal plug and the best timing for these procedures. Inflammation and local infection should be controlled prior to performing these procedures to help avoid retention of proinflammatory tear components that could cause further injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/2,23\">",
"     2,23",
"    </a>",
"    ]. The placement of temporary punctal plugs is technically difficult and should be done in patients with SS by ophthalmologists with a particular interest and expertise in these procedures.",
"   </p>",
"   <p>",
"    Punctal occlusion involves sealing of the lacrimal puncta, through which the tears normally drain to the nose. Several different types of punctual plugs are available, and intracanalicular plugs that do not protrude onto the corneal surface are often preferred and have the added advantage that they can be removed nonsurgically [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of punctal occlusion has been shown in small randomized trials, including a trial in which occlusion was performed unilaterally in a randomly chosen eye and was compared with the contralateral eye [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/45\">",
"     45",
"    </a>",
"    ], and in uncontrolled studies, in which comparisons were made with baseline assessments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. In these reports and in our experience, a majority of patients have improvement in symptoms and a decreased need for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    , although less than 25 percent of patients have improvement in an objective measure of dryness or corneal surface injury and although 25 to 35 percent of plugs are extruded during follow-up.",
"   </p>",
"   <p>",
"    Temporary collagen punctal plugs may be used initially to ensure that punctal occlusion does not result in excess tear accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/49\">",
"     49",
"    </a>",
"    ]. However, temporary plugs often do not adequately block the puncta. Thus, failure to improve comfort with these temporary devices does not preclude the use of permanent punctal occlusion. Also, temporary plugs can be used to avoid a permanent change in patients who might regain near-normal lacrimal function with appropriate therapy.",
"   </p>",
"   <p>",
"    Complications of &ldquo;permanent&rdquo; (silicone) punctal plugs include local infections and pyoderma-like reactions around the plugs; plug extrusion that is sometimes associated with the pyoderma granulomas; and migration into the canaliculi [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The potential risk for infection (dacrylitis) is a concern but is low. Discomfort may occur with plug insertion. Another complication in some patients is tear overflow due to punctal injury from the procedures.",
"   </p>",
"   <p>",
"    When indicated, laser or hand-held thermal cautery can be used for a permanent closure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/52\">",
"     52",
"    </a>",
"    ]. Surgical occlusion is also an alternative. Punctal occlusion is a tear preservation strategy; as a result, it is of little benefit unless supplemented with artificial lubricants in those with minimal to no tear production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3377170\">",
"    <span class=\"h1\">",
"     SEVERE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with frequent or constant symptoms should be managed initially using the measures described for mild and moderate disease, but they may not respond adequately to these approaches alone. Patients with severe disease may require intensification of therapies already being employed or additional interventions. (See",
"    <a class=\"local\" href=\"#H3377156\">",
"     'Initial therapy and mild disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3377163\">",
"     'Moderate disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Signs of severe disease may include marked or severe punctate corneal erosions, filamentary keratitis, and less than 5 mm of wetting on the Schirmer&rsquo;s test.",
"   </p>",
"   <p>",
"    For these patients, additional measures that may be employed, depending in part upon patient preference, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , which may be increased to three or four times daily [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/32\">",
"       32",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H14287856\">",
"       'Topical cyclosporine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      A two-week pulse with topical glucocorticoids, under the direction of an ophthalmologist, followed by a gradual taper (see",
"      <a class=\"local\" href=\"#H1749513\">",
"       'Topical glucocorticoids'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Use of moisture goggles or other physical barriers for tear conservation (see",
"      <a class=\"local\" href=\"#H94900550\">",
"       'Physical barriers'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Permanent punctal occlusion by cautery. In patients who have experienced inadequate benefit from temporary or other types of punctal plugs, this method may last longer than laser treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1749892\">",
"       'Punctal occlusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic antiinflammatory and immunosuppressive therapies (see",
"      <a class=\"local\" href=\"#H93302381\">",
"       'Systemic antiinflammatory and immunosuppressive therapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=see_link\">",
"       \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other therapies, including certain types of contact lenses, autologous tear preparations, and topical nonsteroidal antiinflammatory drugs (NSAIDs), which may be of benefit in selected patients (see",
"      <a class=\"local\" href=\"#H93301747\">",
"       'Other therapies'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93302381\">",
"    <span class=\"h2\">",
"     Systemic antiinflammatory and immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally do not use systemic antiinflammatory or immunosuppressive therapies for the treatment of sicca symptoms alone, such as dry eye and mouth, although some of these agents have beneficial effects in patients with systemic and extraglandular disease, and a few have shown some efficacy for sicca symptoms, including dry eye.",
"   </p>",
"   <p>",
"    The following agents may be beneficial for dry eye symptoms in patients with SS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      (HCQ), which has shown mixed results. These include a study showing improvement in symptoms and objective measures of dryness and corneal surface findings in 50 to 60 percent of 40 patients who received HCQ (6 to 7",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      for 24 to 48 months [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/54\">",
"       54",
"      </a>",
"      ]; a study of 32 patients treated for at least 48 months with HCQ, who were found to have significant worsening in dry eye symptoms and in objective measures of dryness and corneal epithelial findings three months following discontinuation of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/55\">",
"       55",
"      </a>",
"      ]; a small series of 21 patients showing nonsignificant benefit in dry eye findings but significant benefit for dry mouth [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/56\">",
"       56",
"      </a>",
"      ]; and a randomized two-year crossover trial involving only 19 patients that failed to demonstrate any significant benefit in ocular symptoms or findings, despite some improvement in signs of inflammation including acute phase reactants and hyperglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      , which has shown limited evidence of benefit for dry eye (or dry mouth), despite evidence of benefit for systemic and extraglandular manifestations of SS. Some benefit was suggested in a randomized trial involving 30 patients in only one of three measures of lacrimal gland function (corneal staining with lissamine green, but not Schirmer&rsquo;s testing or tear break-up time) and statistically significant improvement in subjective scoring of ocular dryness compared with baseline values [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/58\">",
"       58",
"      </a>",
"      ]. In another randomized trial involving 17 patients, there was no significant change in glandular function six months after administration of rituximab, and there was no improvement in Schirmer&rsquo;s test scores or in the unstimulated salivary flow rate at that time point [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/59\">",
"       59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In trials with rituximab, increased tear flow was only noted in patients with early stages of SS who had residual basal tear flow at study baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/58,60\">",
"       58,60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other medications that have been evaluated in patients with SS without objective evidence of benefit include systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/61\">",
"     61",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/62\">",
"     62",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/63\">",
"     63",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/64\">",
"     64",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/65\">",
"     65",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93301747\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several interventions may be of benefit in selected patients with severe disease. However, these approaches should only be prescribed under the direction and ongoing care of an ophthalmologist with particular interest and expertise in treating patients with dry eyes due to Sj&ouml;gren&rsquo;s syndrome. (See",
"    <a class=\"local\" href=\"#H93302119\">",
"     'Contact lens use'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3377261\">",
"     'Topical NSAID drops'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93302119\">",
"    <span class=\"h3\">",
"     Contact lens use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gas-permeable scleral lenses may be used in selected patients with dry eye [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Ophthalmologists may also use &ldquo;bandage&rdquo; contact lenses to help retard tear evaporation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/68\">",
"     68",
"    </a>",
"    ]. Some patients may tolerate contact lenses for treatment of diminished visual acuity unrelated to SS. The use of &ldquo;rigid&rdquo; lenses (that do not maintain their integrity by imbibing fluid from the tear film) is preferred.",
"   </p>",
"   <p>",
"    Contact lens use may increase the risk of corneal abrasion, and patients should consult with their dry eye ophthalmologist before considering their use. Lenses should not be worn overnight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93301729\">",
"    <span class=\"h3\">",
"     Autologous tears",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials and other studies have shown that a dilution of patient&rsquo;s sera (termed &ldquo;autologous tears&rdquo;) may be useful in patients with refractory dry eye [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    prepared from umbilical cord serum have also been used in severely dry patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3377261\">",
"    <span class=\"h3\">",
"     Topical NSAID drops",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical nonsteroidal eye drops can provide symptomatic relief, but their use requires extreme caution and close monitoring by an ophthalmologist experienced in their use. Close monitoring is important because of the risk of corneal injury due to the associated reduction in corneal sensitivity with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Potential adverse effects limit the use of these agents and include corneal-scleral melts, perforation, and severe keratopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/76\">",
"     76",
"    </a>",
"    ]. Treatment must be promptly discontinued if corneal epithelial defects develop or worsen during use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3377268\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to established immunosuppressive or immunomodulatory agents, there are other therapies requiring further study for which there is some evidence suggesting potential benefit. These include dietary fatty acid supplements, such as fish oil and evening primrose oil, and other investigational therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93303388\">",
"    <span class=\"h2\">",
"     Dietary fatty acid supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral preparations of omega-6 essential fatty acids, linoleic acid, gamma-linolenic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/77\">",
"     77",
"    </a>",
"    ], or evening primrose oil [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/78\">",
"     78",
"    </a>",
"    ] modestly improved ocular symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs in small randomized trials. Omega-3 fatty acids contribute to the lipid layer of the eye, which retards evaporation and, thus, preserves the integrity of the tear film. One large cohort study has suggested that a diet enriched in omega-3 fatty acid consumption is associated with a decreased incidence of dry eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93303395\">",
"    <span class=\"h2\">",
"     Other investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other investigational therapies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       Artificial tears",
"      </a>",
"      containing androgenic hormones [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diquafosol, which is a P2Y2 agonist (a purinogenic stimulator) and topical secretagogue for chloride ions that increases aqueous tear volume in animal models by directly transporting fluid across the serosal membranes of the ocular surface and that may also stimulate mucin secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/1,83\">",
"       1,83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      15-S HETE, which is an arachidonic acid metabolite under investigation as a mucin-specific secretagogue. It selectively stimulates human conjunctival cells in vitro and on the corneal surface of rabbits [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/84-86\">",
"       84-86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rebamipide [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/87\">",
"       87",
"      </a>",
"      ], ecabet sodium [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/88\">",
"       88",
"      </a>",
"      ], and gefarnate [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/89\">",
"       89",
"      </a>",
"      ]. These are topical medications applied as eye drops, which have been used in Japan as gastroprotective agents and which have been tried in dry eye therapy because of their mucin secretory action [",
"      <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3377289\">",
"    <span class=\"h1\">",
"     RISKS OF OPHTHALMOLOGIC PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SS may be at increased risk compared with the general population if they undergo certain ophthalmologic procedures, including keratoplasty and blepharoplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85149101\">",
"    <span class=\"h2\">",
"     Keratoplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser keratoplasty for treatment of refractive errors by photoreactive methods such as LASIK&reg; is contraindicated in patients with SS. Such procedures may exacerbate pre-existing dryness and may lead to corneal abrasions in patients with SS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/90-92\">",
"     90-92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85149109\">",
"    <span class=\"h2\">",
"     Blepharoplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgeons performing blepharoplasty should be aware of the dry eye syndrome, since elective surgery on the eyelids can mechanically alter the anatomy sufficiently to aggravate a subclinical condition, resulting in full-blown keratoconjunctivitis sicca. This may occur due to interruption of the neural innervations of the glands of the lids that provide basal stimulation and to the possibility of exposure keratitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/12/26826/abstract/93-96\">",
"     93-96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=see_link\">",
"       \"Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=see_link\">",
"       \"Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3377311\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several approaches should be used for tear conservation in patients with Sj&ouml;gren&rsquo;s syndrome (SS) and dry eyes, including attention to ambient humidity and other environmental factors, attention to medications that exacerbate dryness that are being used for other indications, and use of physical barriers to avoid drying or irritation of the eyes. Particular attention to ocular exposure and care should be given to patients undergoing surgical procedures. (See",
"      <a class=\"local\" href=\"#H94900469\">",
"       'Tear conservation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with SS, we recommend the regular use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      as needed rather than the use of interventions for tear conservation alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Identifying the agent that provides the most comfort for an individual patient is best determined by trying different agents. At night, a longer-acting lubricant ointment may be useful. (See",
"      <a class=\"local\" href=\"#H94901467\">",
"       'Artificial tears'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with itching or increased irritation of the eye with use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      containing preservatives, stabilizers, or solubilizers, and in patients requiring artificial tears and other topical ocular medications containing preservatives more than four times daily, an alternative preparation should be tried, which is preservative-free or which uses a different preservative. (See",
"      <a class=\"local\" href=\"#H94901467\">",
"       'Artificial tears'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H94901481\">",
"       'Choice of replacement fluid'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H94901495\">",
"       'Potential complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blepharitis may complicate SS, and increased ocular irritation from lid margin inflammation and infection may be misinterpreted as an inadequate response to topical therapies. It is important to differentiate from SS because it requires separate treatment rather than intensification of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/14/34017?source=see_link\">",
"       ocular lubricant",
"      </a>",
"      therapy. Unlike SS, blepharitis is often associated with redness of the lower lids, with increased tearing, and with relatively normal Rose Bengal staining. Blepharitis can be worsened by the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      , especially those with high viscosity or those containing preservatives. (See",
"      <a class=\"local\" href=\"#H94901495\">",
"       'Potential complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"       \"Blepharitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ophthalmic emulsion in patients with moderate to severe disease who have not responded adequately to strategies for tear conservation and to the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      , rather than continuing such agents alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Topical cyclosporine (0.05 percent ophthalmic emulsion) is administered as one drop (0.4 mL) twice daily and can be used together with artificial tears. We use topical cyclosporine prior to trials of punctal occlusion. (See",
"      <a class=\"local\" href=\"#H14287856\">",
"       'Topical cyclosporine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical glucocorticoids are beneficial for burning or stinging upon initiation of topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      therapy and in patients with moderate to severe symptoms with signs of inflammation uncontrolled with cyclosporine and other interventions. Their use should be prescribed and monitored by an ophthalmologist. (See",
"      <a class=\"local\" href=\"#H1749513\">",
"       'Topical glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with moderate to severe ocular dryness in whom frequent installation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      and use of topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      is inadequate or impractical, we suggest punctal occlusion, rather than using topical agents alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Punctal occlusion may help to maximize tear preservation and relief of symptoms in such patients. Inflammation should be controlled prior to punctal occlusion. (See",
"      <a class=\"local\" href=\"#H1749892\">",
"       'Punctal occlusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/1\">",
"      Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: current and prospective therapies. Semin Arthritis Rheum 2008; 37:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/2\">",
"      Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/3\">",
"      Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/4\">",
"      Ramos-Casals M, Brito-Zer&oacute;n P, Sis&oacute;-Almirall A, et al. Topical and systemic medications for the treatment of primary Sj&ouml;gren's syndrome. Nat Rev Rheumatol 2012; 8:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/5\">",
"      Yu HD, Chou AH, Yang MW, Chang CJ. An analysis of perioperative eye injuries after nonocular surgery. Acta Anaesthesiol Taiwan 2010; 48:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/6\">",
"      Wolkoff P, N&oslash;jgaard JK, Franck C, Skov P. The modern office environment desiccates the eyes? Indoor Air 2006; 16:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/7\">",
"      Hagan S, Lory B. Prevalence of dry eye among computer users. Optom Vis Sci 1998; 75:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/8\">",
"      Blehm C, Vishnu S, Khattak A, et al. Computer vision syndrome: a review. Surv Ophthalmol 2005; 50:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/9\">",
"      Rosenfield M. Computer vision syndrome: a review of ocular causes and potential treatments. Ophthalmic Physiol Opt 2011; 31:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/10\">",
"      Aragona P, Di Stefano G, Ferreri F, et al. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sj&ouml;gren's syndrome patients. Br J Ophthalmol 2002; 86:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/11\">",
"      Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002; 86:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/12\">",
"      Brignole F, Pisella PJ, Dupas B, et al. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol 2005; 243:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/13\">",
"      Condon PI, McEwen CG, Wright M, et al. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol 1999; 83:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/14\">",
"      McDonald CC, Kaye SB, Figueiredo FC, et al. A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond) 2002; 16:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/15\">",
"      Toda I, Shinozaki N, Tsubota K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sj&ouml;gren's syndrome. Cornea 1996; 15:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/16\">",
"      Nilforoushan MR, Latkany RA, Speaker MG. Effect of artificial tears on visual acuity. Am J Ophthalmol 2005; 140:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/17\">",
"      Lenton LM, Albietz JM. Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis. J Refract Surg 1999; 15:S227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/18\">",
"      Pucker A, Marrone M, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev 2012; :CD009729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/19\">",
"      Baudouin C, Labb&eacute; A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010; 29:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/20\">",
"      Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/21\">",
"      Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/22\">",
"      Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010; 88:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/23\">",
"      Foulks GN. Treatment of dry eye disease by the non-ophthalmologist. Rheum Dis Clin North Am 2008; 34:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/24\">",
"      Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 1984; 14:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/25\">",
"      Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj&ouml;gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999; 159:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/26\">",
"      Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sj&ouml;gren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002; 46:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/27\">",
"      Papas AS, Sherrer YS, Charney M, et al. Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sj&ouml;gren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study. J Clin Rheumatol 2004; 10:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/28\">",
"      Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/29\">",
"      Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea 2007; 26:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/30\">",
"      Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sj&ouml;gren syndrome: a systematic review. JAMA 2010; 304:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/31\">",
"      Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 2005; 89:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/32\">",
"      Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 2009; 28:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/33\">",
"      Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000; 118:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/34\">",
"      Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005; 112:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/35\">",
"      Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol 2009; 147:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/36\">",
"      Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sj&ouml;gren syndrome. Ophthalmology 1999; 106:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/37\">",
"      Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000; 19:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/38\">",
"      Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004; 138:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/39\">",
"      Berdoulay A, English RV, Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol 2005; 8:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/40\">",
"      Nell B, Walde I, Billich A, et al. The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. Vet Ophthalmol 2005; 8:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/41\">",
"      Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003; 136:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/42\">",
"      Hong S, Kim T, Chung SH, et al. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sj&ouml;gren's syndrome. J Ocul Pharmacol Ther 2007; 23:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/43\">",
"      Tanure MA, Cohen EJ, Sudesh S, et al. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea 2000; 19:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/44\">",
"      Hamano T. Lacrimal duct occlusion for the treatment of dry eye. Semin Ophthalmol 2005; 20:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/45\">",
"      Mansour K, Leonhardt CJ, Kalk WW, et al. Lacrimal punctum occlusion in the treatment of severe keratoconjunctivitis Sicca caused by Sj&ouml;gren syndrome: a uniocular evaluation. Cornea 2007; 26:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/46\">",
"      Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 2001; 131:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/47\">",
"      Gilbard JP, Rossi SR, Azar DT, Heyda KG. Effect of punctal occlusion by Freeman silicone plug insertion on tear osmolarity in dry eye disorders. CLAO J 1989; 15:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/48\">",
"      Willis RM, Folberg R, Krachmer JH, Holland EJ. The treatment of aqueous-deficient dry eye with removable punctal plugs. A clinical and impression-cytologic study. Ophthalmology 1987; 94:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/49\">",
"      Farrell J, Patel S, Grierson DG, Sturrock RD. A clinical procedure to predict the value of temporary occlusion therapy in keratoconjunctivitis sicca. Ophthalmic Physiol Opt 2003; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/50\">",
"      Musadiq M, Mukherji S, Sandramouli S. Pyogenic granuloma following silicone punctal plugs: report of two cases. Orbit 2005; 24:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/51\">",
"      Kim BM, Osmanovic SS, Edward DP. Pyogenic granulomas after silicone punctal plugs: a clinical and histopathologic study. Am J Ophthalmol 2005; 139:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/52\">",
"      Cohen EJ. Punctal occlusion. Arch Ophthalmol 1999; 117:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/53\">",
"      Vrabec MP, Elsing SH, Aitken PA. A prospective, randomized comparison of thermal cautery and argon laser for permanent punctal occlusion. Am J Ophthalmol 1993; 116:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/54\">",
"      Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sj&ouml;gren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996; 5 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/55\">",
"      Yavuz S, Asfurolu E, Bicakcigil M, Toker E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome. Rheumatol Int 2011; 31:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/56\">",
"      Rihl M, Ulbricht K, Schmidt RE, Witte T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome. Rheumatology (Oxford) 2009; 48:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/57\">",
"      Kruize AA, Hen&eacute; RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sj&ouml;gren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993; 52:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/58\">",
"      Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sj&ouml;gren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/59\">",
"      Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sj&ouml;gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/60\">",
"      Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sj&ouml;gren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/61\">",
"      Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sj&ouml;gren's syndrome. Clin Exp Rheumatol 1993; 11:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/62\">",
"      Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sj&ouml;gren's syndrome. Clin Exp Rheumatol 1996; 14:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/63\">",
"      van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sj&ouml;gren's syndrome: a phase II pilot study. Ann Rheum Dis 2007; 66:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/64\">",
"      Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sj&ouml;gren's syndrome. J Rheumatol 1998; 25:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/65\">",
"      Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sj&ouml;gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj&ouml;gren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/66\">",
"      Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sj&ouml;gren's syndrome: a pilot study. J Rheumatol 2004; 31:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/67\">",
"      Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sj&ouml;gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004; 50:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/68\">",
"      Romero-Rangel T, Stavrou P, Cotter J, et al. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000; 130:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/69\">",
"      Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007; 26:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/70\">",
"      Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sj&ouml;gren's syndrome. Br J Ophthalmol 1999; 83:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/71\">",
"      Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 2005; 139:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/72\">",
"      Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984; 27:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/73\">",
"      Yoon KC, Heo H, Im SK, et al. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol 2007; 144:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/74\">",
"      Aragona P, Stilo A, Ferreri F, Mobrici M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sj&ouml;gren's syndrome patients. Eye (Lond) 2005; 19:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/75\">",
"      Avisar R, Robinson A, Appel I, et al. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea 2000; 19:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/76\">",
"      Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 2001; 108:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/77\">",
"      Aragona P, Bucolo C, Spinella R, et al. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sj&ouml;gren's syndrome patients. Invest Ophthalmol Vis Sci 2005; 46:4474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/78\">",
"      Oxholm P, Manthorpe R, Prause JU, Horrobin D. Patients with primary Sj&ouml;gren's syndrome treated for two months with evening primrose oil. Scand J Rheumatol 1986; 15:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/79\">",
"      Miljanovi B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr 2005; 82:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/80\">",
"      Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 2003; 22:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/81\">",
"      Sullivan DA, Edwards JA. Androgen stimulation of lacrimal gland function in mouse models of Sj&ouml;gren's syndrome. J Steroid Biochem Mol Biol 1997; 60:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/82\">",
"      Pillemer SR, Brennan MT, Sankar V, et al. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sj&ouml;gren's syndrome. Arthritis Rheum 2004; 51:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/83\">",
"      Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004; 23:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/84\">",
"      Gamache DA, Wei ZY, Weimer LK, et al. Corneal protection by the ocular mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced corneal defect. J Ocul Pharmacol Ther 2002; 18:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/85\">",
"      Jumblatt JE, Cunningham LT, Li Y, Jumblatt MM. Characterization of human ocular mucin secretion mediated by 15(S)-HETE. Cornea 2002; 21:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/86\">",
"      Gipson IK, Hori Y, Arg&uuml;eso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf 2004; 2:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/87\">",
"      Urashima H, Okamoto T, Takeji Y, et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 2004; 23:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/88\">",
"      Peral A, Dom&iacute;nguez-God&iacute;nez CO, Carracedo G, Pintor J. Therapeutic targets in dry eye syndrome. Drug News Perspect 2008; 21:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/89\">",
"      Nakamura M, Endo K, Nakata K, Hamano T. Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo. Exp Eye Res 1997; 65:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/90\">",
"      Campos M, Takahashi R, Tanaka H, et al. Inflammation-related scarring after photorefractive keratectomy. Cornea 1998; 17:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/91\">",
"      Di Pascuale MA, Liu TS, Trattler W, Tseng SC. Lipid tear deficiency in persistent dry eye after laser in situ keratomileusis and treatment results of new eye-warming device. J Cataract Refract Surg 2005; 31:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/92\">",
"      Albietz JM, Lenton LM, McLennan SG. Dry eye after LASIK: comparison of outcomes for Asian and Caucasian eyes. Clin Exp Optom 2005; 88:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/93\">",
"      Graham WP 3rd, Messner KH, Miller SH. Keratoconjunctivitis sicca symptoms appearing after blepharoplasty. The \"dry eye\" syndrome. Plast Reconstr Surg 1976; 57:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/94\">",
"      Rees TD, Jelks GW. Blepharoplasty and the dry eye syndrome: guidelines for surgery? Plast Reconstr Surg 1981; 68:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/95\">",
"      Rees TD, LaTrenta GS. The role of the Schirmer's test and orbital morphology in predicting dry-eye syndrome after blepharoplasty. Plast Reconstr Surg 1988; 82:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/12/26826/abstract/96\">",
"      Saadat D, Dresner SC. Safety of blepharoplasty in patients with preoperative dry eyes. Arch Facial Plast Surg 2004; 6:101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14922 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26826=[""].join("\n");
var outline_f26_12_26826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3377311\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3377135\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3377142\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3377156\">",
"      INITIAL THERAPY AND MILD DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94900469\">",
"      Tear conservation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94900496\">",
"      - Environmental management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H94901188\">",
"      Operating room and perioperative management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94900523\">",
"      - Avoidance of medications causing dryness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94900550\">",
"      - Physical barriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94901467\">",
"      Artificial tears",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24634482\">",
"      - Artificial tear composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94901481\">",
"      - Choice of replacement fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94901495\">",
"      - Potential complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3377163\">",
"      MODERATE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14287258\">",
"      Lubricant ointments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14287856\">",
"      Topical cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1749513\">",
"      Topical glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1749892\">",
"      Punctal occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3377170\">",
"      SEVERE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93302381\">",
"      Systemic antiinflammatory and immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93301747\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93302119\">",
"      - Contact lens use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93301729\">",
"      - Autologous tears",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3377261\">",
"      - Topical NSAID drops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3377268\">",
"      INVESTIGATIONAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93303388\">",
"      Dietary fatty acid supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93303395\">",
"      Other investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3377289\">",
"      RISKS OF OPHTHALMOLOGIC PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85149101\">",
"      Keratoplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85149109\">",
"      Blepharoplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3377311\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/14922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/14922|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/39/38524\" title=\"table 1\">",
"      Differential dx Sjogrens synd",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25784?source=related_link\">",
"      Dry eyes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=related_link\">",
"      Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=related_link\">",
"      Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_12_26827="CRRT";
var content_f26_12_26827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Continuous renal replacement therapies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Blood access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Arteriovenous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Continuous arteriovenous hemofiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Continuous arteriovenous hemodialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Continuous arteriovenous hemodiafiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Venovenous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Continuous venovenous hemofiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Continuous venovenous hemodialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Continuous venovenous hemodiafiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Slow continuous ultrafiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Slow low efficiency dialysis or dialfiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Slow low efficiency daily dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Extended daily dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Peritoneal access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuous equilibrium peritoneal dialysis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26827=[""].join("\n");
var outline_f26_12_26827=null;
var title_f26_12_26828="Laboratory findings in ILD";
var content_f26_12_26828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory findings in the interstitial lung diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukopenia",
"       </td>",
"       <td>",
"        Sarcoidosis; connective tissue disease; lymphoma; drug-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytosis",
"       </td>",
"       <td>",
"        Hypersensitivity pneumonitis; lymphoma; systemic vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilia",
"       </td>",
"       <td>",
"        Eosinophilic pneumonia; sarcoidosis; systemic vasculitis; drug-induced (sulfa, methotrexate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"       <td>",
"        Sarcoidosis; connective tissue disease; drug-induced; Gaucher's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemolytic anemia",
"       </td>",
"       <td>",
"        Connective tissue disease; sarcoidosis; lymphoma; drug-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normocytic anemia",
"       </td>",
"       <td>",
"        Diffuse alveolar hemorrhage syndromes; connective tissue disease; lymphangitic carcinomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercalcemia",
"       </td>",
"       <td>",
"        Sarcoidosis; lymphangitic carcinomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary sediment abnormalities",
"       </td>",
"       <td>",
"        Connective tissue disease; systemic vascultiis; drug-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypogammaglobulinemia",
"       </td>",
"       <td>",
"        Lymphocytic interstitial pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypergammaglobulinemia",
"       </td>",
"       <td>",
"        Connective tissue disease; sarcoidosis; systemic vasculitis; lymphocytic interstitial pneumonia; lymphoma; silicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiglomerular basement membrane antibody",
"       </td>",
"       <td>",
"        Goodpasture's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antineutrophil cytoplasmic antibody",
"       </td>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's); Churg-Strauss syndrome; microscopic polyangiitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum precipitating antibodies",
"       </td>",
"       <td>",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphocyte transformation test",
"       </td>",
"       <td>",
"        Chronic beryllium disease; aluminum potroom workers disease; gold-induced pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevation of LDH",
"       </td>",
"       <td>",
"        Alveolar proteinosis; idiopathic pulmonary fibrosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Schwarz MI, King TE Jr, Cherniack RM. General principles and diagnostic approach to the interstitial lung diseases. In: Murray JF, Nadel JA (Eds), Textbook of Respiratory Medicine, 2nd ed, Philadelphia, WB Saunders Co, 1994, pp. 1803-1826.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26828=[""].join("\n");
var outline_f26_12_26828=null;
var title_f26_12_26829="Epinephrine and plasma K";
var content_f26_12_26829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epinephrine lowers the plasma potassium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plasma potassium concentration during an infusion of epinephrine (in physiologic doses) in six patients pretreated with a placebo or a thiazide diuretic for seven days. The plasma potassium concentration fell in both groups, but reached potentially dangerous levels in the diuretic-treated patients who had mild baseline hypokalemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Struthers, AD, Whitesmith, R, Reid, JL, Lancet 1983; 1:1358.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26829=[""].join("\n");
var outline_f26_12_26829=null;
var title_f26_12_26830="Termination of Rx in RA";
var content_f26_12_26830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frequent termination of therapy in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 412px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative termination incidence of therapy with gold, penicillamine, or sulphasalazine in patients with rheumatoid arthritis. Ninety-two percent of patients were no longer taking gold after five years, and the median time to treatment termination was six to seven months. Similar findings were seen with the other two drugs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Situnayake, RD, Grindulis, KA, McConkey, B, Ann Rheum Dis 1987; 46:177.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26830=[""].join("\n");
var outline_f26_12_26830=null;
var title_f26_12_26831="Diagnosis acute porphyria";
var content_f26_12_26831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment decision tree: Suspected acute porphyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 469px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This decision tree shows the recommended laboratory evaluation of patients with concurrent symptoms suggesting an acute porphyria, indicating how the diagnosis is established or excluded by biochemical testing and when specific therapy should be initiated.",
"    <br/>",
"    This schema is applicable only to symptomatic patients who may be having an acute attack. Levels of ALA and porphobilinogen may be less increased in HCP and VP and decrease more quickly with recovery than in AIP; urine porphyrins may remain increased, but are subject to nonspecific increases. Mutation detection provides confirmation and greatly facilitates detection of relatives with latent porphyria.",
"    <div class=\"footnotes\">",
"     PBG: porphobilinogen; ALA: 5-aminolevulinic acid; ADP: ALA dehydratase porphyria; AIP: acute intermittent porphyria; HCP: hereditary coproporphyria; VP: variegate porphyria; ALAD: ALA dehydratase; PBGD: PBG deaminase; CPO: coproporphyrinogen oxidase; PPO: protoporphyrinogen oxidase.",
"     <br>",
"      * Proceed in parallel with both treatment and confirmation of type of porphyria present.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Decision tree supplied by Karl Anderson, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_12_26831=[""].join("\n");
var outline_f26_12_26831=null;
